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PREFACE
This dissertation is laid out in two chapters. Chapter 1 is the Introduction, with a brief
overview of the G-protein coupled receptors (GPCR), G-proteins, their effector
molecules and downstream signaling partners with emphasis on parathyroid hormone
(PTH) and parathyroid hormone receptor’s (PTH1R) history, and literature. Chapter1 also
discusses the significance of this research, the existing gaps and how our work will help
bridge some of the gaps in this research area. The second chapter contains the manuscript
“Comparison of PTH peptides, PTH (1-34) and PTH (7-34): effects on cell signaling,
proliferation and gene expression in Saos2 human osteosarcoma cell line” that is
currently in preparation for submission.
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ABSTRACT
Mamidanna, Gayatri. Ph.D. The University of Memphis, August 2017. Comparison of
PTH peptides, PTH (1-34) and PTH (7-34): effects on cell signaling, proliferation, and
gene expression in the Saos2 human osteosarcoma cell line. Major Professor: Judith A.
Cole, Ph.D.
Parathyroid hormone PTH (1-34)’s ability to increase bone formation has made it
therapeutically beneficial, but its impact on bone resorption and chance of osteosarcoma
limits its usefulness. In mice, bovine PTH (7-34) induces bone formation without bone
resorption, suggesting its usefulness in osteoporosis. However, PTH (7-34)’s impact on
bone function must be comparable to or better than that produced by PTH (1-34) and its
effect on bone in the presence of endogenous PTH has not been assessed. Using human
Saos2 osteosarcoma cells, we examined the effects of PTH (1-34) and PTH (7-34), alone
and in combination, on second messenger production, DNA synthesis, ERK and Akt
activation, activity of pro-apoptotic caspase 3, and changes in expression of selected
genes. PTH (1-34) increased cAMP, a response competitively antagonized by PTH (734). PTH (7-34) alone reduced basal cAMP production, indicating it is an inverse agonist
in these cells. PTH (1-34) also increased intracellular calcium. While PTH (7-34) had no
effect alone, it enhanced the effect of PTH (1-34) on calcium at low doses. A 24 h
treatment with PTH (1-34) increased cell number, while PTH (7-34) had no effect alone
and blocked the responses to PTH (1-34). PTH (1-34) produced a rapid increase in ERK
activity at 5 min while PTH (7-34) slowly increased ERK activity with a maximal
response appearing between 30-60 min. However, ERK activation was lost when both
peptides were present. While PTH (1-34) decreased Akt activity and PTH (7-34) had no
effect, when both peptides were present together, Akt activity increased at low dose of
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PTH (1-34). In general, PTH (1-34) decreased expression of genes involved in osteoblast
differentiation (Runx2, osteocalcin, and Col1A1) a response mimicked by PTH (7-34).
Co-incubation with both peptides produced responses comparable to PTH (1-34) alone.
PTH (1-34) stimulated pro-proliferative genes (p21cip1, BMP2) and increased
RANKL/OPG ratio while PTH (7-34) did not. Taken together, these data suggest that
PTH (7-34) may not be a suitable anabolic agent in vivo.
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Chapter 1
Introduction
Signal transduction is a process whereby an external signal is received by the cell and
transformed into second messengers and downstream physiological responses. External
signals can be hydrophobic like steroid hormones that diffuse across plasma membrane
and bind to their receptors in the cytoplasm or nucleus. Ligand-bound receptors then bind
to the DNA of target genes and regulate gene expression. Hydrophilic signals like peptide
hormones, neurotransmitters, and growth factors cannot cross the plasma membrane and
thus bind to a cell surface receptor. Cell surface receptors are integral membrane proteins
like receptor tyrosine kinases (RTK) and G-protein coupled receptors (GPCRs), and upon
ligand binding, the receptor undergoes conformational changes which recruit effectors to
the cytoplasmic regions of the receptor.
Typical integral membrane protein receptors contain three domains. The first is
the N-terminal extracellular domain which contains most of the ligand-binding region.
Glycosylated amino acids are typically located in this domain and are responsible for the
proper folding of the receptor during protein synthesis and trafficking to the plasma
membrane.(1) The second domain is the transmembrane domain (TMD) which spans the
lipid bilayer and functions to pass the signal from outside the cell to the cytoplasmic
domain of the receptor. This transmembrane domain may consist of a single α-helical
peptide as in a RTK or seven-α helices organized as a bundle in a GPCR. Generally, the
transmembrane helices are made of 20-30 hydrophobic amino acids with some polar
amino acids located at the end of the helix. In the GPCRs, the helices are almost
perpendicular to the bilayer and form bundle-like structures in which individual helices
are linked by loops of variable size. Ligand binding triggers a change in orientation of the
1

TMD, which leads to a conformational change of the intracellular loops leading to an
interaction with G-proteins inside the cell. The last domain is the intracellular (IC)
domain which, in GPCR’s, is made up of three intracellular loops (ICL) and the Cterminal tail. The three ICLs generate a signal ‘informing’ the cell of the receptor’s
conformation change leading to G-protein interactions, while the C-terminal tail is a
target for post-translational modification. For RTKs, IC region contains the tyrosine
kinase activity of the receptor, and auto phosphorylation sites for interaction with
proteins containing SH2 and PTB domain.
G-Protein Coupled Receptors
The GPCRs are one of the largest and most diverse families of membrane
receptors and are encoded by more than 800 genes in humans.(2) They are also called
seven transmembrane (7TM) receptors since their transmembrane domains traverse the
lipid bilayer seven times with their amino terminal outside the cell and carboxyl terminal
inside the cell. More than 1000 different GPCRs have been identified and they mediate
cellular responses to hormones, neurotransmitters and are responsible for vision, smell,
and taste.(3) Upon activation by ligand, the receptor undergoes a conformational change
and couples to G-proteins on the cytoplasmic side, which then activate an effector
molecule. A remarkable feature of the GPCR family of receptors is the sheer number of
receptors available to bind ligands with diverse shape, size, and chemical properties.
Though all ligands have been observed to bind in a pocket in the extracellular region of
the transmembrane domain, different ligands penetrate to different depths within this
pocket. The GPCRs are classified (Fig.1) into four families (Class A, B, C and Frizzled
(also called F)) based on the following criteria; 1) sequence similarity, 2) size of the
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extracellular loop, 3) presence of key residues (usually cysteines in the extracellular
loops) and 4) the formation of di-sulfide bonds.
a Ligands ranging
from light, small
molecules, peptides
to proteins

c Ions and small

b Peptide

molecules

hormones

d Wnt
proteins

Fig. 1. Classification of GPCRs. The GPCRs can be divided into 4 major families. a) Class A members,
characterized by a series of conserved residues. In most family members a disulfide bridge connects
extracellular loops 2 and 3. b) Class B members, characterized by a long extracellular N-terminus
containing cysteine residues presumably forming a network of disulfide bridges. c) Class C members,
characterized by a very long N-terminus forming the extracellular ligand binding site with conserved
disulfide linkages to form a dimer. d) Frizzled receptors with GPCR-like transmembrane spanning regions
fused with one or more functional N-terminal domains (11).

Class A receptors: These receptors have conserved cysteine residues which form
disulfide bridges between extracellular loop II and III and a consensus E/DRY (glutamic
acid, aspartic acid, arginine, and tyrosine) motif in intracellular loop II. This E/DRY
motif is thought to be responsible for regulation of the receptor conformation, as
mutations in Glu and Asp residues lead to a constitutively active receptor. In addition,
mutation of the Arg residue results in a decrease in ligand affinity.(4) In most receptors,
the key amino acid residues in TM 3, 6 and 7 form a groove in the ligand binding pocket
and the differences in these amino acids contribute to ligand specificity. Over the past
decade, more than 75 structures of 18 different receptors have been determined, which
have provided remarkable insights into the structure and functional diversity in this
family.(2) Some of the receptors that belong to this family are 1, 2, β1 and β2
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adrenergic receptors as well as serotonin, dopamine, muscarinic acetylcholine, histamine,
and chemokine receptors.
Class B receptors: These receptors have a large extracellular amino terminal
domain and contain six cysteine residues that form three conserved disulfide bridges. The
corticotropin releasing hormone and human glucagon receptors were sequenced in 1985
(5)

and 1994,(6) respectively and the crystal structures of these two members were solved

in 2013.(7,8) Delay in solving the crystal structures was due to the inherent instability of
the receptors. The parathyroid hormone receptor also belongs to this family.
Class C receptors: These receptors are characterized by an exceptionally large
amino terminal domain which contains the “venus flytrap” module and a highly variable
cysteine rich domain with the intracellular carboxy terminal tail. The crystal structure for
the metabotropic glutamate receptor was solved in 2000.(9) The gamma-amino butyric
acid-B (GABA-B) receptors and the calcium sensing receptors also belong to this class of
receptors.
Class F frizzled receptors: These receptors are unique because their activity is
modulated by interactions with additional plasma membrane receptors. The classic
examples are the Frizzled receptors (FRZ) that interact with low-density lipoprotein
receptor-related proteins 5 and 6 (Lrp 5/6) and upon binding of Wnt initiate signaling.(10)
To date, there is no crystal structure for the fizzled receptor, but in 2013, the structure for
Smoothened receptor (SMO), a member of this class, was resolved. The SMO receptor
shows high sequence similarity to FRZ receptors. The extracellular domain consists of a
cysteine- rich domain (CRD), a linker domain, the 7TM domain and an intracellular
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carboxy terminal domain.(8) The CRD of the Frizzled receptor binds to the endogenous
glycoprotein ligand Wnt, but the function of the CRD in SMO remains unclear.
G-protein-dependent signaling by GPCRs
Receptor activation and conformation change: All GPCRs share a common
7TM topology and mediate cellular responses through external signals. The GPCRs share
a general mechanism of activation that begins upon ligand binding to the N-terminal
extracellular domain, resulting in a conformation change in the 7TM domains. This
change in conformation of the 7TM domains results in recruitment of G-proteins to the
intracellular loops 2 and 3, activation of the G-proteins followed by activated G-proteins
coupling to effector molecules which trigger signaling cascades to mediate physiological
processes.(11)
Heterotrimeric G-Proteins as OFF-ON switches: The GPCRs are so called
because they couple to heterotrimeric GTP-binding G-proteins on the cytoplasmic side of
the cell membrane. Heterotrimeric G-proteins are the most prominent partners in the
signal transduction of the GPCR and belong to the large family of regulatory GTPases
that bind GTP for activation as shown in Fig 2. G-proteins function as “off-on switches”
in cellular responses. This “switch” function of the G-protein is a cyclic transition
between an ‘active’ GTP-bound form to ‘inactive’ GDP-bound form which is produced
by intrinsic GTPase in the  subunit hydrolyzing GTP to GDP. Both the GTP-GDP
exchange and GTPase activity of the  subunit are too slow to effectively signal and
these processes are accelerated by guanine nucleotide exchange factors (GEFs) and
GTPase activating proteins (GAPs), respectively. GEFs catalyze the exchange of GDP
for GTP and for heterotrimeric G-proteins, the agonist-bound receptor is the GEF. GAPs
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accelerate GTP hydrolysis and reduce the active GTP-bound state. This is an important
step in controlling the rate of signal transmission by diminishing signaling during
continual exposure to receptor-ligand. Effectors such as phospholipase β (PLCβ) and
regulators of G-protein signaling (RGS) are GAPs and increase the intrinsic rate of GTP
hydrolysis by the G subunit, thus decreasing the time of the activated state of G.
Activated G-proteins pass the signal to the effector molecules which are typically enzyme
molecules like adenylyl cyclase (AC) and PLCβ. Activation of AC and PLCβ increase
the concentration of diffusible second messengers like cyclic AMP (cAMP),
diacylglycerol (DAG), inositol trisphosphate (IP3) and Ca+2 which trigger downstream
affects.(12)

Fig. 2. Activation/inactivation cycle of heterotrimeric G proteins.
Heterotrimeric G proteins serve as OFF/ON switches for GPCR signaling. (1)
Upon ligand binding, the activated receptor stimulates GDP-GTP exchange,
(2) leading to the dissociation of  -GTP from the βsubunits and their
activation of effector molecules. (3) The GTPase activity of the -subunit
hydrolyzes GTP and (4) -GDP reassociates with the β subunits.
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Types of G-proteins and their effectors: Heterotrimeric G-proteins are
composed of , β, and  subunits with the β subunits being constitutively associated. 
subunits have a molecular weight between 39-46 kDa, have a binding site for GTP/GDP,
and intrinsic GTPase activity. All subunits show diversity with at least 16 genes for , 5
for β, and 12 for  in human and mouse. Subunits β and  are 36 kDa and 8 kDa,
respectively and upon release from the  subunit interact with effector molecules like
AC, PLCβ, Ca+2 channels, and K+ channels and are thus responsible for signal
transduction.(12) Most functions of signal transmission by heterotrimeric G-proteins are
defined by the G subunit. Based on amino acid sequence similarity and the effector
proteins they activate, G proteins are divided into four classes: Gs, Gi, Gq, and
G12/14.
Gs- AC- cAMP signaling: Gs activates all isoforms of AC, resulting in the
production of the second messenger cAMP. Gs is a substrate for cholera toxin, which
catalyzes the ADP-ribosylation of an arginine residue in the Gs subunit. This arginine
contacts the phosphate group of the bound GTP and is indirectly involved in GTP binding
and hydrolysis. This modification of arginine leads to inactivation of the GTPase of the 
subunit, resulting in its constitutive activation, as well as the constitutive activation of
AC, which catalyzes the formation of cAMP from ATP. Cyclic AMP is a wide spread
signaling molecule whose functions are mediated by the activation of cAMP-dependent
protein kinase (PKA), the GEF exchange protein activated by cAMP (Epac), and the
opening of cAMP-gated ion channels.
Protein kinase A, B (Akt) and C make up the ABC protein kinase family. Of
these, PKA is the best characterized member. PKA has two regulatory subunits that
7

suppress the activity of two catalytic subunits. Increases in cAMP lead to co-operative
binding of two molecules of cAMP to each regulatory subunit of PKA. Upon binding of
four molecules of cAMP to the two regulatory subunits, PKA disassociates into the
regulatory subunit dimer with cAMP bound and two free catalytic subunits which are
released from inhibition. These free catalytic subunits can now phosphorylate
serine/threonine residues on specific substrate proteins. A large portion of cellular PKA
is associated with the plasma membrane via special anchoring proteins called AKAPs (a
kinase anchoring protein). The formation and degradation of cAMP and activation of
PKA occur at spatially restricted sites on the inner side of the plasma membrane and are
thus localized. The concentration of cAMP that leads to activation of PKA is relatively
small; in most tissues a 2-3 fold increase in cAMP is sufficient for maximum
physiological effect. PDE terminates cAMP signaling by catalyzing the hydrolysis of
cAMP to 5’ AMP. Activated PKA phosphorylates and activates phosphodiesterase 4
(PDE4), and this mechanism enables PKA to control its own steady-state levels.(13)
PKA is also involved in cAMP- stimulated transcription of genes that have a
cAMP response element (CRE) in their promoter region. Increases in cAMP lead to
activation of PKA which phosphorylates the transcription factor CRE binding-protein
(CREB) at Ser133. Phosphorylated CREB stimulates transcription of target genes.(12,14)
Gi-PLCβ / PKC and Ca+2 signaling: Gi was initially defined by its ability to

inhibit AC activation. The Gt (transducin) and Gg (gustducin) proteins are also
classified as Gi based on sequence homologies.(12) In addition, the β subunits activate
phospholipase β (PLCβ), which cleaves phosphatidylinositiol-4, 5- bisphosphate (PIP2) to
generate DAG which activates protein kinase C (PKC) and IP3 which releases calcium
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from intracellular stores. All members of Gi are inhibited by pertussis toxin which ADP
ribosylates a cysteine residue close to the C-terminus of G subunit, preventing the
disassociation of the  and β subunits.
Gαq-PLCβ / PKC and Ca+2 signaling: The Gq family is composed of Gq,
G11, G14 and G15/16 (15). Gq proteins are activated by Pasturella multocida toxin
leading to activation of PLCβ. Effector function of PLC is based on its stimulation by
Gq and the β complex disassociated from GI,(16) where each of the four isoforms of
PLCβ have different sensitivity to Gq and β subunits. Hydrolysis of PIP2 by PLCβ
produces IP3 and DAG. DAG is hydrophobic and remains in the membrane, where it has
at least two functions; it is a source for release of arachidonic acid from which
biosynthesis of prostaglandins take place. The second important function of DAG is
stimulation of PKC. The IP3 receptor is a ligand-gated calcium channel where binding of
IP3 opens the channel and releases Ca+2, stored at high concentrations in the endoplasmic
reticulum (ER), into the cytosol.
PKC is a serine /threonine kinase, which was identified by its requirement for
second messengers DAG and Ca+2 for activation.(12) There are 11 subtypes of PKC,
classified into 3 families according to the structure of the N-terminal regulatory domain
which determines their sensitivity to cofactors DAG and Ca+2. The 3 families of PKC are
1) Classical/ conventional PKC- cPKC (, βI, βII,) which require DAG and Ca+2 for
activation, 2) Novel PKC- nPKC (, , , ) which are DAG-dependent and Ca+2independent, and 3) Atypical PKC- aPKC (, , ) which are DAG- and Ca+2 independent. PKCs (classical and novel) have high affinity for the DAG mimics phorbol
esters which are frequently used to identify PKC-dependent events. The sensitivity to
9

Ca+2, DAG, and specific binding of phorbol esters have long been considered the main
characteristics of this enzyme.
Cells at rest maintain a low intracellular concentration of Ca+2 at ~100 nM and
this rapidly increases to µM range upon stimulation. This increase in intracellular calcium
ions ([Ca+2]i) can operate over a wide temporal range from microseconds to hours to
regulate different cellular responses. An important feature of calcium’s dynamic nature is
the appearance of transient signals, with the rising phase of each transient being the ‘on’
and the falling phase the ‘off’ reaction. At any given time, the level of Ca+2 is determined
by the balance between on and off reactions. Ca+2 is also regulated by spatial locations.
For example, voltage operated channels (VOC) in the pre-synaptic region are associated
with synaptic vesicles and thus produce highly localized release of Ca+2 to trigger
exocytosis.(17)
Signal termination: In addition to the G-proteins that couple and bind to the
ICLs of the receptor, other proteins interact with this region to modulate function. Upon
ligand binding and receptor activation, the signal is initiated by G-protein coupling and
the signal is ‘on’. This signal must also be terminated, a response initiated by G-protein
coupled receptor kinases (GRKs). GRKs phosphorylate the C-terminal tail of the
agonist-occupied receptor and recruit β-arrestins. β-arrestins sterically hinder G-proteins
from coupling to the receptor, resulting in weakening of the signal, a process called
“desensitization”. The β-arrestins also recruit other proteins involved in clathrin-mediated
endocytic machinery, resulting in receptor internalization and downregulation, where the
receptor is removed from the cell surface. This internalized receptor is either recycled
back to the cell surface or is degraded in the lysosomal compartments. Until recently, it
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was thought that β-arrestins functioned solely to desensitize and downregulate the
GPCRs, but it is now clear that they act as scaffolding molecules for other proteins to
assemble and conduct G-protein-independent signals.(18,19)
β-arrestin(s) and signaling: β-arrestins 1 and 2 (also known as arrestins 2 and 3)
along with visual rod (arrestin 1) and cone (arrestin 4) constitute a small family of
cytosolic adaptor proteins.(20) β-arrestins were first discovered in β2-adrenergic receptor
(β2AR) signaling, where it was shown that they desensitized or “arrested” the signal
generated by G-proteins.(21) It has now been established that GRKs and β-arrestins serve
as universal regulators of G-protein-dependent signaling by GPCRs. Traditionally, it has
been thought that GPCRs mediate signal transduction exclusively through G-protein
coupling. But, signaling scaffolds of β-arrestin may become localized on endosomes and
make the β-arrestin-dependent signal temporally and spatially distinct from the Gprotein- dependent signal. There is now evidence to show that some ligands can
preferentially activate β-arrestins while blocking or minimally activating G-proteins or
vice versa. This ligand-directed signaling is called “biased agonism” where the receptor
activated signal transduction is through one of the multiple signaling pathways available.
This provides evidence that the receptor-agonist complex has multiple conformations that
can couple to different effector molecules inside the cell.(22)
Biased agonism is best explained in a model where a GPCR’s active
conformations are able to activate the range of receptor-coupled signaling pathways as
shown in Fig.3. A balanced ligand (typically the endogenous ligand) would stabilize the
active conformation for all the downstream pathways, whereas a biased ligand would
stabilize a subset of signals. For example, ligands can show bias for either G-protein or β-
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arrestin, a potentially beneficial aspect of these agonist, as they could selectively target
signaling and /or block or reduce unwanted receptor responses like tolerance or toxicity.
In the past decade, a number of ligands for GPCRs have been identified that either
activate G-protein or β-arrestins.(23)
One of the best characterized receptors for G-protein bias is the µ-opioid receptor
(µOR). β-arrestin2 (-/-) mice experienced prolonged and enhanced morphine-induced
analgesia and greater and more efficient control of G-protein coupling.(24) A G-protein
biased ligand will preferentially engage G-protein coupling with a marked reduction in
receptor phosphorylation and recruitment of β-arrestin2. This leads to delay in
desensitization and internalization of the receptor thus minimizing tolerance. This Gprotein biased ligand translates to increased analgesia with a reduction in adverse effects
like severe nausea, vomiting, GI dysfunction and respiratory depression. These studies
showed that the analgesic efficacy of µ-OR can be differentially regulated by β-arrestin2
in vivo. Currently, the G-protein biased µOR TRV130 made by Trevena Inc. is in human
clinical trials because it increases analgesia and limits adverse effects.(25)
The angiotensin I receptor (AT1R) is also a widely-studied model for β-arrestin
bias. The AT1R recognizes angiotensin II (AngII), a critical cardiovascular hormone that
functions as a terminal effector of the renin-angiotensin system. Activation of the AT1R
stimulates both G-protein and β-arrestin-dependent signals which promote growth,
hypertrophy and proliferation of cardiac myocytes, constriction of vascular smooth
muscle cells and myocyte contractility. The newly identified ligand Sar1-D-ala8-AngII
(SII, TRV120027)
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Fig.3. Schematic representation of hypothetical GPCRs with distinct ‘active states’. Each of the
receptor couples to downstream G-protein (Gs, Gq/11, G12/13) and non-G-protein (arrestin 2 and 3)
effectors with different efficiency. Full agonist (A) will produces a full system response in all
downstream effectors, as seen in a conventional model. In contrast, ‘biased’ agonists (B) engage different
active receptor conformations with variable intrinsic efficacy, which allows them to activate some
downstream pathways while antagonizing others. The ability to induce “mixed” effects permits biased
agonists to qualitatively change GPCR signaling. (22)

binds to the AT1R and activates only β-arrestin-dependent pathways leading to a
decrease in mean arterial pressure, increase in cardiac performance and pressure, and
stroke volume in anesthetized rats. In contrast, the unbiased endogenous AngII decreases
cardiac performance.(26,27) AT1R and β-arrestin-dependent signals include ERK, Rho,
and Src leading to cellular responses including protection from apoptosis, protein
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synthesis and stimulation of cardiomyocyte contractility which make the β-arrestinbiased ligand a potential therapeutic cardioprotective agent.(28)
GPCR-induced MAPK-ERK activation
Mitogen activated protein kinases (MAPK) are a group of proline-directed
serine/threonine kinases that are important regulators of cell growth and differentiation.
There are five main MAPK pathways in eukaryotes and are named accordingly to the
terminal kinase in the three-kinase cassette. The MAPKs include a) extracellular signal
regulated kinase (ERK 1/2), b) c-Jun N-terminal kinase, c) p38, d) ERK3/4, and e)
ERK5.(29) The MAPK pathways are composed of a cassette of three protein kinases
acting sequentially, starting with a mitogen activated protein kinase kinase kinase
(MAPKKK), followed by a mitogen activated protein kinase kinase (MAPKK) and a
mitogen activated protein kinase (MAPK).(29) In the three-kinase cassette, the first kinase
MAPKKK is activated through phosphorylation and/or because of an interaction with a
small GTP binding protein of the Ras/Rho family in response to extracellular stimuli.
This leads to phosphorylation and activation of the dual specificity MAPKK. MAPKK
then stimulates MAPK activity through dual phosphorylation of T and Y residues inside a
consensus T-X-Y domain located in the activation loop of the kinase domain.
One of the best characterized MAPKs is ERK1/2. ERK1/2 is activated by agonists
for RTKs as well as by GPCRs, cytokines, osmotic stress and microtubule
disorganization. The mammalian ERK1/2 module consists of the MAPKKKs A-Raf, BRaf, and Raf-1, the MAPKKs MEK1 and 2, and the MAPKs ERK1 and 2.(29) The best
described mechanism of activation involves growth factor-mediated activation of RTKs.
Ligand-induced receptor dimerization in RTKs promotes receptor activation and
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autophosphorylation of the tyrosine residues in the intracellular domain. These
phosphorylated tyrosine residues recruit other proteins like growth factor receptor-bound
protein 2 (Grb2), which then recruits the GEF “son of sevenless” (SOS) to stimulate the
exchange of GDP for GTP on Ras, which then allows Ras to interact with Raf, and
activate ERK1/2.
GPCR-dependent ERK1/2 activation can occur in a Gs-cAMP-Epac-Rap1dependent fashion or through a PKA-induced activation of A-Raf.(30) Gq- dependent
stimulation of PLCβ leads to increase in PKC activity and the subsequent activation of
ERK1/2 through a Pyk2-SOS-Grb2-Ras-C-Raf mechanism.(31-33) Activated GPCRs can
also transactivate RTKs by stimulating the metalloprotease-mediated release of EGFR
ligands as seen in Fig. 4.

Fig.4. GPCR-induced MAPK activation. GPCR activation leads to the stimulation of EGFR and
the subsequent activation of ERK cascade. This process is known as GPCR –EGFR transactivation
and involves different mediators such as the Src family of kinases, calcium-dependent focal
adhesion kinase Pyk2, calcium and PKC depending on the cell type. GPCR transactivation of the
EGFR occurs through metalloprotinase-dependent release of EGFR ligands that activate the EGFR
and lead to ERK activation.(33)
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These ligands bind to and activate EGFR and result in ERK activation. GPCRs can also
recruit and activate members of the Src family of non-RTK that can lead to ERK
activation through a ligand-independent transactivation of EGFR.(31) In the past two
decades, it has been shown that various GPCRs, including the AT1R, β1 adrenergic
receptor (β1AR), endothelial type A receptor (ETA), and PTH1R have β-arrestin biased
ligands that activate ERK in a G-protein-independent manner and have potential
therapeutic uses.(23)
Parathyroid Hormone Receptor: signaling and function
Parathyroid Hormone Receptor (PTH1R): PTH1R is a member of the Class B
GPCR family and binds two different endogenous peptides, parathyroid hormone (PTH)
and parathyroid hormone-related peptide (PTHrP). The PTH1R was cloned in the early
1990s from opossum kidney cells and rat sarcoma (ROS17/2.8) cells.(34,35) Both
receptors have high homology, with about 78% amino acid identity. The human PTH1R
has 593 amino acids (Fig. 5) and was isolated by hybridization techniques using two
cDNA libraries constructed from human kidney and the human osteoblast-like sarcoma
(Saos2) cell line.(36) The human receptor has 91% and 81% identity with rat and opossum
receptor, respectively.(36)
In humans, the PTH1R gene is located on chromosome 3p and consists of 14
coding exons.(37) The receptor has a 22 amino acid signal peptide at the amino terminal
end, which is removed during processing, and the receptor is transported to the plasma
membrane. PTH1R transcripts are highly expressed in bone and kidney, but are also
present in vascular smooth muscle, adrenal glands, bladder, brain, breast, cerebellum,
heart, ileum, liver, lung, ovary, skeletal muscle, skin, spleen, stomach, uterus, and
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testes.(38) The PTH1R expressed in bone and kidney regulates calcium and phosphate
homeostasis in response to activation by PTH and is described in detail below.

Fig.5. The Human PTH1R. The ‘snake’ diagram of PTH1R illustrates the receptor’s 593
amino acids in a topological arrangement. The receptor has a large ECD of ~165 amino acids, 7
TMDs, connecting loops and C-terminal tail of about 130 amino acids. (43) The extracellular
domain (ECD) has 4 pairs of cysteine (C) that form disulfide bond network that is conserved in
family B GPCRs. ECD also has 4 glycosylated asparagine (N) residues that mediate interaction
with ligand. Seven serine (S) residues in the C-terminal are phosphorylated upon agonist
activation and mediate recruitment of β-arrestins. C-terminal ETVM sequence mediates
interaction with NHERF-Na/H exchange regulator factor, family of proteins, a scaffolding
protein used to assemble a complex of the PTH1R and PLCβ.

A second PTH receptor (PTHR2) was identified in 1995 through a homologybased cDNA cloning strategy aimed at identifying paralogs of PTH1R.(39) This receptor
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has 70% amino acid identity with PTH1R and is expressed in various parts of the brain
including the hypothalamus, as well as the pancreas, thyroid parafollicular cells, testis,
placenta, the heart, and vascular smooth muscle.(39,40) Studies in vitro and in vivo
suggested that PTH and PTHrP are not the endogenous ligands for PTHR2.
Tuberoinfundibular peptide 39 (TIP39) isolated from bovine hypothalamic tissue was
purified, sequenced, and shown to be the ligand that binds PTHR2.(41) In-situ
hybridization in mice showed high expression of TIP39 in brain including hypothalamus
and brain stem areas as well as testis. These studies have suggested a neuroendocrine role
in hypothalamus, and in testis TIP39 is essential for spermatogenesis. During evolution,
gene duplication events have occurred and this has resulted in a speciation process with
PTH receptor paralogs which may be present in some species and not the others. The
third PTH receptor (PTH3R)(42) is found in birds and fish but not in mammals. No known
biological function or endogenous ligand has been found for this receptor, and its role in
calcium regulation in the aquatic environment or in egg shell calcification is unknown.(43)
Parathyroid Hormone (PTH): PTH in mammals is a single chain 84 amino acid
peptide that is synthesized and secreted by the parathyroid glands. PTH is encoded by a
single mammalian gene and in humans is present on chromosome 11. PTH was initially
isolated from bovine parathyroid glands, and the amino acid sequence was determined by
Brewer et al.(44) PTH is produced as a pre-pro hormone, composed of a 25 amino acid
pre-sequence, followed by a 6 amino acid signal peptide for protein trafficking. This
mature peptide is packaged in secretory vesicles within the parathyroid chief cells. The
production and secretion of PTH is regulated by blood ionized calcium concentration
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where extracellular calcium is sensed by the calcium sensing receptor (CaSR) at the
surface of the cells of parathyroid gland.(45)
Bovine PTH (bPTH) consists of 84 amino acids with alanine at the amino
terminal end and glutamine at the carboxy terminal. The identification of biologically
active fragments of the 84 amino acid peptide was determined by dilute acid hydrolysis,
which cleaved at aspartate residues present between amino acid 31 and 45. Since
aspartate was not found in the first 30 amino acids of the PTH peptide, it was determined
that the amino-terminal portion contained the biological activity region of the hormone.
This lead Potts and colleagues(46) to synthesize a peptide consisting of residues 1-34 by
solid phase methods using the bPTH sequence. The synthetic peptide was identical to the
native peptide in that it: a) stimulated adenylyl cyclase in both bone and kidney, b)
elevated blood calcium, and c) increased renal excretion of both cAMP and phosphate in
rats and dogs.
The amino terminal portion of the synthetic bovine PTH (1-34) was studied in
detail to define the minimum structural requirements essential for biological activity and
if receptor binding requirements were identical in kidney and bone. It was shown in 1971
that the amino acids 1-13 of synthetic bovine PTH (1-34) had no biological activity but
receptor binding was not investigated at this time. This suggested that some portion of
14-34 amino acid sequence was required for biological activity(46) and led to peptide
truncations and substitutions to identify the amino acid residues responsible for biological
activity. Removal of the N-terminal alanine decreased, and removal of the first two
amino acids (alanine, valine) abolished all biological activity known at this time.(47) To
identify the size of the fragment that is necessary for binding to the receptor, Rosenblatt
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and colleagues synthesized a number of peptides with progressively shorter N-terminal
ends, including bPTH (3-34), bPTH (7-34), bPTH (10-34), bPTH (15-34), bPTH (20-34),
bPTH (25-34) and bPTH (28-34). In receptor binding studies, they found that bPTH (2534) can bind to receptors whereas bPTH (28-34) cannot. PTH peptides that have the C-

Fig.6. Two-site model for binding. This model illustrates the 2 site mechanism of PTHPTH1R interaction where the C-terminal portion of PTH (1-34) in a -helical conformation,
interacts with ECD of the receptor and the N-terminal portion of the ligand binds to the TMD
of the receptor, leading to conformation change involved in receptor activation and coupling
of heterotrimeric G-proteins.(43)

terminal 10 amino acids e.g. PTH (25-34), satisfy the structural requirements for binding
to the PTH1R in vitro.(48)
The working hypothesis in the 1980s was that amino acids 15-34 of PTH (1-34)
were required for receptor binding, and amino acid residues 1-14 were responsible for
signaling events after binding. As the full-length peptide is 84 amino acids, the biological
role of the amino acids 35-84 is still unknown. The carboxy terminal portion of the 1-34
fragment represents the principal binding domain, which contacts the amino terminal
extracellular domain of the receptor and establishes the initial docking interaction. After
the peptide has docked, the amino terminal portion of the peptide, which contains the
principal determinants for signaling, interacts with the transmembrane domains of the
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receptor and results in a conformational change leading to receptor activation and
coupling to G-proteins.(43) This 2-step model of binding, as shown in Fig. 6, was further
supported by utilizing chimeric human/rat PTH1R receptors,(49) point mutations in
extracellular regions of TMD V and VI,(50) and identification of specific contacts between
ligand and receptor using photoaffinity crosslinking studies.(51-54) For example:
crosslinking studies have demonstrated that amino acid residues at position 1 and 2 in
bPTH (1-34) crosslink to Met425 in TMD6 of the receptor, suggesting that this region of
the receptor is essential for activation as TMD6 is next to IL3, which appears to couple to
Gs.(53) The 3D structure of the PTH1R has not yet been resolved, but the solution
structure of an antagonist complexed to the N-terminal ECD of adenylate cyclaseactivating polypeptide receptor (PACAP), a member of class B receptor family, was
determined by NMR in 2007(55) and led to the current model of the ligand-receptor
binding. Based on this model, upon ligand binding to the ‘groove’ between TMD 5 and 6,
the ECD folds over and covers the opening of the EC surfaces of the TMD, similar to a
“lid covering a pot”, thus trapping the ligand in the TMD active site.(43)
PTH1R and G-protein coupling: When ligand binds to the PTH1R, there is a
conformational change, and the residues in the ICLs of the receptor contribute to Gprotein coupling. Some of the residues in the ICLs involved in G-protein coupling have
been identified by mutational studies. In the opossum kidney PTH1R receptor,
substitution of Ala for Lys382 in ICL3 decreases Gs and Gq signaling, suggesting that
Lys382 is involved in G-protein coupling.(56) Similarly, random mutations performed in
ICL2 of the rat PTH1R identified Lys319 as critical for Gq coupling as mutating this
residue to Glu abolished Gq signaling without affecting that of Gs.(57) These data

21

indicate that the 2nd and 3rd ICLs are important for G-protein coupling and the specific
amino acids determine which G-protein couples with the receptor.
Addition of the non-hydrolysable guanine nucleotide (GTPS) or PTH to ROS
17/2.8 and UMR 106 cells grown in labeled [3H]-inositol resulted in an increase in the
production of labeled inositol bisphosphate (IP2) and IP3.(58,59) These data suggested the
presence of G-proteins coupled to phosphoinositide-specific PLC. To determine if
activation of PLC was a result of receptor coupling to Gq and not due to β subunits
released from Gs, PTH1R and different subunits of Gq family (Gq, G11, G14,
G15, and G16) proteins were co-transfected in COS7 cells.(60) This study showed that
the PTH1R interacted with all Gq but not with Gs proteins to generate inositol
phosphates. At this time, it was not determined that β subunits are released from Gi.
PTH increases cAMP through Gs and it was Schwindinger et al.(61) that provided
evidence for direct coupling of PTH1R to Gs, Gq and Gi using non-hydrolysable
photoreactive GTP analogs. To identify the portion of the receptor that is involved in Gprotein coupling, a series of receptor truncations were performed by Schneider et al in
1994 and revealed that the full length receptor activated only Gs, while a severely
truncated receptor with 128 amino acids missing from the C-terminal end activated Gs,
Gq, and Gi.(62) This was the first instance where a GPCR could promiscuously couple
to three G subunits, suggesting that the C-terminal residues in a receptor are critical for
G-protein coupling.
Activation of Adenylyl Cyclase: In 1968, it was shown for the first time that
bPTH activated AC and generated cAMP, a response seen within a minute after PTH was
added to plasma membrane fractions of rat renal tissue.(63) In the following year, the
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effect of PTH on AC in fetal rat calvaria showed that the hormone caused a rapid increase
in cAMP production. AC in the skeleton and kidney was sensitive to activation by PTH,
and these data led the authors to propose that PTH binds to specific sites on the plasma
membrane of bone and renal cortical cell, which we now know to be the PTH1R.(64)
Cyclic AMP mediates many of the physiological effects of PTH on bone, and work
performed using PDE inhibitors and a cAMP analogue demonstrated an increase in blood
calcium in parathryoidectimized rats,(65,66) and increased bone resorption manifested by
an increase in calcium release from bone explants.(67) Cyclic AMP was the first second
messenger to be described upon activation of PTH1R by PTH. These data established
cAMP as a second messenger for PTH-dependent regulation of bone remodeling.
The first instance of a post-receptor event in hormonal regulation of bone cells
was demonstrated by treatment of ROS17/2.8 rat osteosarcoma cells and primary cells
from rat calvaria with PTH, prostaglandin E2, and prostacyclin PG12. There was a rapid
and dose-dependent increase in cAMP and PKA activity upon treatment with each agent.
Maximal activation of PKA occurred at ligand concentrations that were sub maximal for
cAMP production, indicating that only a fraction of the cAMP produced was required for
maximal activation of PKA.(68) Various studies performed in subsequent years have
implicated PKA in various downstream events including ERK activation and
transcription of genes regulated by PTH.(14)
Activation of Phospholipase Cβ: In late 1970s and 80s it was shown that treating
kidney cells with PTH increased the incorporation of [32P] into phosphatidic acid and
phosphatidylinositol. This increase was independent of cAMP but dependent on
continuous protein synthesis.(69-71) Studies conducted in rat tibia corroborated the
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increase in phosphatidylinositol upon PTH administration, and this increase was dosedependent.(72) Studies in the opossum kidney (OK) cell line, primary cultures of canine
proximal tubule cells (CPT), and canine basolateral cell membrane (BLM), demonstrated
that PTH stimulates phosphoinositide turnover and production of DAG and IP3 through
activation of PLCβ. This was the first study in primary cells showing that PTH increased
IP3, and DAG in a dose-dependent manner.(73) In the UMR 106 sarcoma cell line, PTH
produced a transient, dose-dependent increase in intracellular calcium, IP3, and DAG.
The calcium transient was rapid and not affected by chelation of extracellular calcium or
blockade of calcium channels, suggesting that calcium was released from intracellular
source.(74,75) Stimulation of PKC by the PKC activator-tumor promoting phorbol acetate
(TPA) increased intracellular Ca+2 with a lag phase, and this was blocked by calcium
channel blockers, indicating this source of calcium is extracellular and this could trigger
calcium release from intracellular stores. Treatment with 4-phorbol, which does not
activate PKC, did not increase intracellular calcium, indicating that this increase in Ca+2
is PKC-dependent.(76)
Since it was shown that PTH activates phospholipid metabolism, studies were
carried out in ROS17/2.8 cells to determine if PTH can influence PKC activity.
Incubation of ROS17/2.8 cells with PTH or phorbol ester resulted in an increase in PKC
activity in the membrane fraction. These effects of PTH or phorbol ester were dosedependent and suggest a potential role for PKC in the mechanism of action of PTH in
bone cells.(77)
PTH and ERK signaling: Numerous reports of PTH’s anabolic effect in bone
and proliferative effects in kidney lead investigators to search for the signaling

24

pathway(s) mediating these effects. Since ERKs are involved in cell proliferation, its
regulation in bone cells was examined. In UMR 106 and ROS 17/2.8 cells, rat PTH (134) inhibited ERK in a rapid and sustained manner, and this was mimicked by the AC
activator forskolin, the cAMP analogue 8-bromo cAMP, and potentiated by a PDE
inhibitor, but not by saturating concentrations of bPTH (3-34), which is unable to activate
AC. PKA inhibitors abolished PTH-dependent inhibition of ERK activation, indicating
that the response is PKA-dependent. In UMR 106 and ROS 17/2.8 cells, PTH also
inhibited incorporation of [3H]-thymidine, a measure of DNA synthesis. Thus, these data
showed that PTH inhibits proliferation and ERK activation in a PKA-dependent
manner(78) in these cells. In OK cells, bPTH (1-34) resulted in a time- and dose-dependent
activation of ERK that was mimicked by activating PKC with phorbol myristate acetate
(PMA) and PKA by using 8-bromo-cAMP and forskolin. ERK activation was reduced by
MEK and EGFR inhibitors indicating PKA, PKC and EGFR-dependent pathways
mediate the PTH-dependent activation of ERK.(79) Later work performed in UMR-106
cells and primary rat osteoblasts demonstrated activation of PKC and increased DNA
synthesis upon rat PTH (1-34) treatment.(80) Rat PTH (1-34) at 10-12 to 10-11 M was
sufficient to increase ERK activity in these cells, while treatment with a higher
concentration of PTH (10-8 M), PTH (1-31), which activates AC, and 8-bromo-cAMP,
failed to stimulate ERK. In contrast, PMA or a PTH peptide (PTH 13-34) that does not
active AC, stimulated ERK activity, a response blocked by PKC and MEK inhibitors,
indicating that this is a PKC-dependent event. These data suggested that PTH increases
ERK activity in a dose-dependent manner, and the associated increase in DNA synthesis
is PKC-dependent.(80) The opposite effects of rat PTH (1-34) on ERK activity in the
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same cell line is due to the concentrations of PTH used and the different signaling
pathways activated. PTH can transiently increase ERK in Chinese hamster ovary (CHO)
cells transfected with rat PTH1R and in yolk sac carcinoma cells that have endogenous
PTH1R. PTH activated AC and PLC in CHO cells and increased ERK activity, a
response mimicked by forskolin or 8-bromo cAMP, indicating that it was cAMPdependent since PMA had no effect.(81) Taken together, these studies indicate that PTH
regulates ERK activity in a cell-type and a dose-dependent manner.
PTH and β-arrestin/ ERK signaling: Numerous studies in the late 90s
implicated β-arrestins in G-protein-independent signaling(82,83) to ERK. There is
substantial evidence that GPCRs can signal through G-protein-independent and βarrestin-mediated pathways where β-arrestins act as scaffolding molecules for effector
molecules like Src, Ras, ERK1/2 and Jnk.(84) These data led Gesty-Palmer et al.(84) to
investigate the role of β-arrestins in PTH1R stimulated ERK1/2. Human PTH (1-34)
binding to the PTH1R can stimulate both G-protein and β-arrestin-dependent signaling
pathways, and these signals can be selectively engaged by G-protein and β-arrestin biased
ligands. Gesty-Palmer et. al.(84) showed that bPTH (D-Trp12, Tyr34)7-34 [bPTH (7-34)]
activates β-arrestin-mediated signaling in HEK293 cells transfected with PTH1R,
resulting in ERK activation in a temporally and spatially distinct manner by utilizing βarrestins as a scaffold. In contrast, hPTH (1-34), the endogenous ligand activates ERK in
a PKA, PKC, and β-arrestin-dependent manner.(84) Later studies in mice demonstrated
that administration of hPTH (1-34) led to an increase in bone formation indices including
increased osteoblast number, osteoid surface, osteocalcin mRNA and serum
osteocalcin.(85) Bone resorption markers were also increased by hPTH (1-34) as
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evidenced by increase in osteoclast number, RANKL mRNA and urine
deoxypyridinoline (DPD), indicating that bone formation and resorption are coupled.
However, selective activation of β-arrestin2 by the biased ligand bPTH (7-34) did not
increase osteoclast number, RANKL mRNA, and urine DPD, but increased bone
formation markers including osteoblast numbers, trabecular volume and thickness,
osteocalcin mRNA, and serum osteocalcin, a response that was abolished in β-arrestin 2
null mice.(85) This increase in bone formation without bone resorption makes this biased
PTH peptide a promising therapeutic agent for treatment of osteoporosis.
PTH and gene regulation: PTH binds to PTH1R, leading to activation, initiation,
and transduction of the signaling pathways, which regulate transcription factor activity
and gene expression. Some of the transcription factors regulated by PTH are activator
protein (AP1), CREB, Runx2, and ATF2. The AP-1 class of transcription factors is
composed of heterodimers of Fos related factors (c-fos, Fra 1, Fra 2 and Fos B) and Jun
proteins (c-jun, Jun B, and Jun D). These transcription factors contain two domains, a
basic DNA binding region that mediates sequence-specific DNA binding and a leucine
zipper, which holds the two DNA binding regions together. c-fos is a member of the
immediate early gene family and is rapidly and transiently induced upon stimulation by
growth factors, serum, and PTH.(86) ERK1/2 stabilizes the c-fos protein through direct
phosphorylation, thereby allowing c-fos to associate with c-jun and form transcriptionally
active AP-1 complexes.(29) CREB is a prototypical member of cAMP response element
(CRE) binding transcription factor and is phosphorylated and activated in response to
increases in cAMP and calcium. CREB is phosphorylated at Ser133 by PKA, PKC,
calcium /calmodulin dependent kinases II and IV, members of the ribosomal S6 kinase
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family (e.g. p70S6K, p90RSK, RSK2), and mitogen and stress activated kinases 1/2
(MSK1, 2).(14) PTH phosphorylates CREB in a PKA-dependent manner, which then
interacts with the CRE in the promoter region of c-fos gene and upregulates c-fos(87) and
then Fos is available to mediate transcription of genes containing AP1 promoter
elements.(88) The Runt related family of transcription factors (RUNX) is characterized by
a highly conserved 128 amino acid protein domain called ‘runt domain’ that binds the
consensus sequence PyGPyGGTPy (Py, pyrimidine).(89) Runx2 is characterized as an
osteoblast-specific transcription activator, and it regulates expression of genes that
promote osteoblast differentiation. PTH increased the expression and activity of Runx2 in
an in vitro and an in vivo model in a dose-dependent manner.(90) This effect of PTH was
mimicked by forskolin, an AC activator, and it was further demonstrated to be PKAmediated by utilizing a PKA inhibitor.(90) ATF4, is a basic leucine zipper transcription
factor that is a member of the ATF/CREB protein family. ATF4 is required for PTH
induction of osteocalcin gene expression in osteoblasts, where PTH increases ATF4
mRNA, protein, and ATF4 binding to osteocalcin specific element -OSE1.(91)
Several genes related to bone and bone remodeling are regulated by PTH
(See Table 1).(92) PTH decreases the expression of the differentiation markers alkaline
phosphatase, type I collagen, osteopontin, osteonectin, and osteoprotegerin, responses
consistent with PTH’s ability to increase proliferation and prevent differentiation and
mineralization of bone and bone remodeling. PTH increases the expression of tissue
inhibitor of metalloproteinases and tissue plasminogen activator which are involved in
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Table 1. PTH- regulated genes. (92) Below is a table of some of the genes regulated by PTH and their
function.
Gene

Gene
Symbol

Description

Alkaline phosphatase
(ALP)

ALPL

osteoblast differentiation marker.

Collagen Type 1

Col1A1

Major constituent of bone, tendons, ligaments and
skin. Mutation in the coding region of col1 results in
osteogenesis imperfecta.



Osteopontin (OPN)

SPP1

non-collagenous protein in bone matrix and
expressed in OB and osteocytes. May modulate the
nucleation of calcium-phosphate during
mineralization.



Osteocalcin (OCN)

BGLAP

non-collagenous protein present in bone matrix.
Produced by chondrocytes, OBs and odontoblasts.
May interact directly with HA



Osteoprotegerin (OPG)

TNFRSF11B

member of the TNF receptor superfamily. Inhibits
osteoclast formation induced by PTH. The ratio of
OPG/RANKL is a determinant of osteoclastogenesis



Tissue inhibitors of
metalloproteinases
(TIMP)

TIMP1, TIMP2

Matrix metalloproteinases (MMPs) degrade collagen
and ECM. TIMPs inhibit collagenase and MMP13



Tissue plasminogen
activator

PLAT

Involved in bone remodeling. Degrades fibrionectin,
laminin, and proteoglycans and converts MMPs like
pro-collagenase into their active forms



Interleukins IL

IL-6, IL-18

IL18 produced by osteoblasts inhibits osteoclast
formation while exogenous IL6 can stimulate bone
resorption.



Macrophage-CSF (MCSF)

CSF1

M-CSF plays a key role in osteoclast recruitment
and osteoclastogenesis



Connexins(Cx) 43, 45

GJA1, GJC1

Connexins form gap junctions between osteoblasts.
Cx 43 -/- at birth reveals delayed intramembranous
and endochondral ossification and clear skull
abnormalities. Cx 45 -/- is embryonically lethal



Bcl 2

Bcl2

Bcl2 encodes an integral outer mitochondrial
membrane protein that blocks the apoptotic cell
death.



Insulin like growth
factor (IGF-1)

IGF-1

promotes OB proliferation, survival and
differentiation; paracrine mediator of PTH’s
anabolic effects.



Cyclin dependent
kinase inhibitor 1A

CDKN1A

inhibitor of cyclin-dependent kinase 2/4; regulates
cell cycle progression at G1
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PTH effect
 or 

Differentially
based on
peptide

matrix remodeling, as well as IL-6, IL-18 and macrophage-colony stimulating factor (MCSF), which are important mediators in bone resorption and remodeling.(93) It has been
hypothesized that Bcl-2, an integral outer mitochondrial membrane protein that blocks
apoptotic cell death, mediates the effects of PTH in osteoblasts by prolonging the lifespan
of osteoblasts.(94)
PTH as a physiological regulator: PTH plays a key role in maintaining the
levels of calcium in the blood and extracellular tissue and thus responds to the minute-byminute fluctuations of calcium that occur throughout the day. PTH is secreted by the
parathyroid gland when blood ionized calcium falls below a set point (in human ~1.2 ±
0.1 mM), and secretion is inhibited when the set point is reached. Thus, the parathyroid
gland acts as a “calciostat” where it senses the ionized blood calcium levels and adjusts
the secretion of PTH accordingly.(43,45) The primary source of calcium used to increase
plasma calcium is the bone.
The PTH1R is primarily expressed in kidney and bone. PTH elevates serum
calcium by increasing bone resorption, enhancing renal reabsorption of calcium in the
distal tubule, and stimulating calcium absorption in the intestine via vitamin D. Bone is
made up of three types of cells: osteoblasts that make bone extracellular matrix (ECM),
osteocytes that are osteoblasts embedded in the matrix they secreted, and osteoclasts
which resorb bone and play a crucial role in bone remodeling as shown in Fig. 7.(95)
The physiological process of biomineralization (calcification) that occurs in bone tissue
takes place throughout the life span of a human. The mineral ions and the Ca+2 and Pi
play a central role in bone formation. Phosphorous is removed from the circulation and
excreted by the kidney and is stored in the skeleton as a calcium-phosphate complex
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called hydroxyapatite. Osteoblasts present at the bone surface are specialized for
formation and secretion of both organic and inorganic constituents of the ECM. Secreted
calcium phosphate crystals (hydroxyapatite; HA) are deposited in the space between the
triple helical fibers of type I collagen. Pyrophosphate (PPi) is hydrolyzed to Pi, which
promotes mineralization, by tissue-nonspecific alkaline phosphate (TNAP), an ectoenzyme expressed by osteoblasts. The first step in the formation of crystalline HA occurs
within the osteoblast organelles called matrix vesicles (MV), which bud from the
membrane. HA is formed by calcium and Pi, and upon accumulation of HA in

Fig.7. Bone remodeling. Bone formation is performed by osteoblasts which are of
mesenchymal lineage while bone resorption is carried out by osteoclasts that are of
hematopoietic origin. Osteoblasts secret the matrix and when embedded in the matrix are
called osteocytes.(95)

these vesicles, the MV membrane ruptures to release the HA crystals into the ECM and
deposits them between collagen fibrils.(96)
PTH effects in bone are mediated by its binding to the PTH1R on the surface of
bone-forming osteoblasts (Fig. 7) where receptor activation leads to the production of
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receptor activated nuclear factor B ligand (RANKL), osteoprotegerin (OPG), and
macrophage-colony stimulating factor (M-CSF). Macrophages are differentiated into
bone resorbing osteoclasts when RANKL and M-CSF produced by osteoblasts bind to
their receptors on monocytes /macrophages. Osteoclasts (Fig. 7) do not express the
PTH1R, but they have the cell-surface RANK receptor which binds RANKL produced by
the osteoblasts. Osteoblasts also produce OPG, which acts as a “decoy” receptor for
RANKL and competes for binding with RANKL for RANK receptor and decreases
differentiation of hematopoietic precursor cells into osteoclasts. Thus, the ratio of
RANKL/OPG is used as an indicator of osteoclastogenesis. Bone resorption is a multistep process starting with osteoclast attachment to the surface of the bone. Once attached,
the osteoclast forms a “ruffled” membrane at the site of resorption. This contact between
osteoclast and bone surface is defined by the “sealed” zone produced by the ruffled
membrane. Bone demineralization involves acidification of the isolated extracellular
microenvironment, a process mediated by a vacuolar H+-ATPase pump in the ruffled
membrane of the cell. This H+-ATPase pump is maintained by an energy-independent Cl/HCO3 exchanger on the cell’s anti-resorptive surface. Electroneutrality is preserved by a
ruffled membrane Cl- channel coupled to H+-ATPase. The results of these ion
transporting events is the secretion of HCl acid into the resorptive microenvironment(97)
resulting in a pH of ~ 4.5. This acidity mobilizes bone mineral, and then lysosomal
proteases and cathepsin act to degrade organic components of bone resulting in release of
ionized calcium and phosphate.
In the kidney, PTH acts in the renal proximal tubule to inhibit phosphate
reabsorption by decreasing the mRNA and protein expression levels of the sodium-
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dependent phosphate transporter type 2A (NPT2) at the renal brush border.(98) Studies in
OK cells have shown that PTH decreases phosphate reabsorption through the endocytic
retrieval of NPT2 protein from the brush border membrane to the endocytic lysosomal
compartment and its subsequent degradation.(99-101)
The calcium released from bone by osteoclast resorption of mineralized matrix is
conserved by PTH-dependent increases in Ca+2 reabsorption in the distal tubule. PTH
also acts in the distal tubule of the kidney to enhance calcium reabsorption rate by
increasing the expression of calcium transport proteins like transient receptor potential
vanilloid type V channel (TRPV) on the lumenal cell surface.(102) These effects on
calcium and inorganic phosphate occur within minutes of hormone exposure. PTH also
increases expression and activity of the 25(OH) vitamin D3 1 hydroxylase, which
converts 25(OH) D3 into its most active metabolite 1,25 (OH) 2 D3. 1,25 (OH) 2 D3
increases absorption of calcium by the gut via increased expression of the calcium
binding protein calbindin, which facilitates the diffusion of calcium through the cell
interior towards the basolateral membrane.(45,103)
Clinical significance: The parathyroid glands were discovered in the late 19th
century, and to identify their function, were removed in cats and dogs. Parathyroidectomy
led to “tetany”, wherein muscular spasms occur because of calcium deficiency. This led
to the definition of PTH’s functional role as the primary regulator of plasma calcium.
Collip’s work in the 1920s(104,105) focused on the harmful effects of excess or insufficient
PTH, which led to the identification of hyperparathyroidism and hypoparathyroidism,
respectively. Hypoparathyroidism is currently treated with drugs to normalize calcium
and phosphorous levels.(106) Hyperparathyroidism was classified either as primary,
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because of PTH hypersecretion or secondary, which is a result of other clinical conditions
which reduce serum calcium levels leading to PTH secretion (e.g. calcium deficiency,
Vitamin D deficiency, or chronic renal failure).
The biochemical similarities between primary hyperparathyroidism and the
humoral hypercalcemia of malignancy (HHM) indicated the likelihood that epithelial
tumors produce a substance that has actions very similar to PTH. PTHrP was initially
purified and characterized as an adenylyl cyclase activating protein from human breast
carcinoma,(107) human lung cancer cell line,(108) and human renal carcinoma.(109) PTHrP
cDNA clones from human lung cancer cells were isolated and expressed in mammalian
cells.(110) The amino acid sequences of the first 16 residues showed 8 of the 16 residues
were identical to PTH and these were amino acids 2, 3,4, 6,7, 10, 12 and 13.(43,108)
PTHrP also binds to and activates the PTH1R and is known to have several important
physiological roles in skeletal and mammary gland development, calcium transport
during pregnancy, tooth eruption, smooth muscle relaxation, and protection of neurons
from excitotoxicity.(111) Approximately 80 % of malignancy-related hypercalcemia is
mediated by PTHrP.(112) PTHrP is normally produced by tissues such as epithelia,
mesenchymal tissue, endocrine glands, and brain including regions of cortex, the
cerebellum, the hippocampus, hypothalamus, and pituitary,(45,112) and is responsible for
normal physiological functions during development. Both PTH and PTHrP act on the
PTH1R, and to combat hypercalcemia and to treat hyperparathyroidism, considerable
efforts were put forth to design antagonists for the PTH1R. A PTH analogue, [tyrosine
34] bPTH (7-34) NH2 was designed as an antagonist to treat hyperparathyroidism.(113)
This peptide was further modified to [D-Trp12 Tyr34] bPTH (7-34) NH2 to increase its
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affinity.(114) PTH (7-34) is a competitive antagonist of PTH-dependent cAMP
production, and recent studies have shown that it has inverse agonist properties in HEK
and CHO cells transfected with PTH1R.(84,115) In addition, PTH (7-34) has biased
properties in mouse but not rat bone (84,116) as well as some but not all transfected cell
lines.(117,118)
Questions/gaps in literature
The signaling pathways activated by PTH for bone growth and bone resorption
have been well-documented. The discovery that PTH can activate G-protein-independent
and β-arrestin-dependent signaling (84) led to the identification of the concept of “biased
agonism”. A study by Gesty-Palmer et al.(84) demonstrated that bPTH (7-34) produced βarrestin-dependent signals that activate ERK in a manner temporally and spatially distinct
from that produced by hPTH (1-34). Further studies suggest that this β-arrestindependent signaling can increase bone formation without resorption, as evidenced by a
decrease in osteoclast number, RANKL mRNA, and urine DPD.(85) Based on data from
IOP/NOF (International Osteoporosis Foundation, National Osteoporosis Foundation)
2007, there are more than 1.5 million fractures/ year that are attributed to osteoporosis in
the US, and it costs the public health care system about $14 billion a year.(119) Most of
the therapeutic agents available to combat osteoporosis either slow or stop bone loss
(e.g.bisphosphonates which slow the bone resorbing action of osteoclasts or induce
osteoclast apoptosis). The only drug on the market that can promote new bone formation
is hPTH (1-34), but it cannot be administered for more than 2 years to osteoporotic
patients.(120) The human clinical trials using Forteo® were stopped at 18 months due to
the occurrence of osteosarcoma in rats, and thus Forteo® is marketed with a ‘black box’
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warning by the FDA in the USA. The in vivo data from studies using bPTH (7-34) are
promising, as this peptide appears to be able to increase bone formation by uncoupling it
from bone resorption. This characteristic may make it useful for long term treatment of
osteoporosis. To date, the only signaling pathway known to be activated by PTH1R- βarrestin-dependent signaling is ERK. However, little is known about the nature of
signaling produced by bPTH (7-34) as it is present on the background of endogenous
PTH. In vivo studies in mice suggest bPTH (7-34) promotes bone growth, and while these
data are encouraging, the peptide’s impact on signaling and downstream events in the
presence of endogenous PTH (1-34) were not addressed.
Study rationale: For any new therapeutic agent to be approved, it must be
comparable to or better than the existing drug on the market. Our study is the first to
examine the structure-function relationship of hPTH (1-34) and bPTH (7-34) alone and in
combination in an in vitro model using the human Saos2 osteosarcoma cell line. We
examined the differences in signaling, cell proliferation and apoptosis, and gene
expression in response to PTH (1-34) and PTH (7-34) alone and in combination. The
specific aims of the study are to:
Aim 1: Characterize proximate PTH1R signaling by PTH peptides: Bovine
PTH (7-34) has been shown to increase bone formation in mice, but this effect could be a
modification of responses to the endogenous PTH. To investigate this possibility, the
signaling ability of PTH (7-34) was compared to PTH (1-34) using (a) cAMP ELISAs to
measure adenylyl cyclase activation, and (b) fluorometric assays to determine PLCβmediated increases in intracellular calcium. Validation of the proximal signaling events
with PTH (1-34) in Saos2 cells was performed and compared to signal(s) activated by
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PTH (7-34). These data were designed to identify the signaling pathways that PTH (7-34)
activates and if the signaling profile changes when both peptides are administered
together.
Aim 2: Characterize the effect of PTH peptides on proliferation as well as
pro-proliferative and pro-survival signaling: We measured the effect of PTH (1-34)
and PTH (7-34) to promote osteoblast proliferation by (a) using cell proliferation
measured using fluorescence based ds DNA. The contribution of pro-proliferative or prosurvival signaling was determined by (b) using a phosphoantibody cell based ELISA with
a phospho ERK/Akt primary antibody, and (c) apoptosis measurement through a
fluorescence based caspase 3 assay.
Aim 3: Effect of PTH peptides on osteogenic gene expression: We designed
RT2 Profiler Custom PCR arrays with genes involved in bone proliferation and
remodeling, and detected changes in gene expression produced by PTH (1-34) or PTH (734) alone or in combination. We validated mRNA changes using Western blotting to
quantify changes in protein.
We expect to observe that the peptides, when added individually and together,
will have different signaling profiles which in turn will have distinct downstream effects
due to differences in gene regulation.
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Chapter 2
Comparison of PTH peptides, PTH (1-34) and PTH (7-34): effects on cell signaling,
proliferation, and gene expression in the Saos2 human osteosarcoma cell line
Introduction
Bone is a highly-mineralized tissue that provides structural support for the body and
allows movement by providing attachment for muscles. It protects internal organs,
furnishes an environment for hematopoiesis within the bone marrow, and provides
continuous maintenance of calcium and phosphate homeostasis. (1) Bone is constantly
undergoing remodeling, and there is a delicate balance between bone formation by
osteoblasts and bone resorption by osteoclasts. This process is regulated by local and
endocrine factors and when it is out of balance, leads to osteoporosis (thinning of bone
leading to weak and brittle bone) or osteopetrosis (abnormally dense bone prone to
breakage).(2) Osteoporosis is a result of excessive bone resorption, which increases the
risk of fracture in the aging population. Based on data from IOF/NOF 2007
(International Osteoporosis Foundation / National Osteoporosis Foundation), more than
1.5 million fractures per year are attributed to osteoporosis in the US, costing the public
health care system about $14 billion a year.(3)
Parathyroid hormone (PTH) is an endocrine factor that is secreted by the
parathyroid gland and is the primary regulator of calcium and phosphate homeostasis.
Full length PTH consists of 84 amino acids, but the amino-terminal peptide PTH (1-34)
has been shown to have all known biological activity.(4) In bone, PTH increases
resorption, resulting in release of calcium and phosphate from the mineralized matrix. In
kidney, PTH increases calcium reabsorption in the distal tubule while, inhibiting the
reabsorption of phosphate in the proximal nephron. PTH also affects calcium absorption
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from the gut by promoting the synthesis of 1,25 (OH)2 vit D3, an agent that increases the
expression of the calcium binding-protein calbindin, which facilitates the diffusion of
calcium across the cell towards the basolateral membrane.(5)
The anabolic properties of PTH were first observed in the 1930s,(6) when rats
administered parathyroid gland extract had markedly denser bones compared to untreated
littermates. It was a few decades later when it was identified that PTH, when
administered intermittently, induced bone formation by: a) promoting differentiation
and/or stimulating proliferation of osteoblasts, b) inhibiting osteoblast apoptosis, c)
reducing the negative effects of peroxisome proliferative activator gamma receptor
(PPAR) on osteoblast differentiation, and d) enhancing Wnt-β catenin signaling by
inhibiting sclerostin.(2,7-9) These observations suggested that PTH (1-34) would be useful
as a therapeutic intervention in osteoporosis. However, continuous administration of PTH
(1-34) leads to bone loss,(10-13) suggesting that the manner in which PTH (1-34) is
administered alters its effects in bone. In 2002, recombinant human PTH (1-34),
marketed as Forteo® or teriparatide, was approved as the first drug to promote anabolic
bone formation. Clinical data with Forteo® have shown increases in bone mineral density
(BMD) and reduced risk of vertebral and hip fracture in humans.(3) However, the drug
cannot be administered for more than 2 years in a lifetime,(14) as continuous
administration may cause osteosarcomas. Thus, there is a therapeutic need for a drug that
could be used long-term.
The effects of PTH are mediated by the PTH1R, a GPCR that belongs to the Class
B family of GPCRs. The N-terminal end of the receptor is involved in ligand binding,
while the intracellular loops and the C-terminal tail are involved in G-protein-dependent
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signal transduction and signal termination. In a ligand-bound receptor, the C-terminal
amino acids are phosphorylated by G-protein receptor kinases (GRKs), and β-arrestins
are recruited to these phosphorylated residues. β-arrestins sterically hinder the G-proteins
from coupling to the receptor and result in a weakening of the signal, a process known as
‘desensitization’. β-arrestins also recruit clathrin-mediated endocytic machinery to the
receptor resulting in internalization and downregulation. It was initially thought that βarrestins were only responsible for receptor desensitization and downregulation, but a
number of studies have shown that β-arrestins act as scaffolding molecules for other
proteins to assemble and transduce signals which are independent of G-protein
coupling.(15)
The PTH1R is primarily found in bone and kidney and is responsible for the
minute-to-minute regulation of plasma calcium. The PTH1R activates adenylyl cyclase
(AC)-(cAMP)-protein kinase A (PKA) through Gαs and phospholipase C (PLC)diacylglycerol (DAG)/inositol trisphosphate (IP3)-protein kinase C (PKC) and calcium
through Gαq.(16,17) A number of studies in different models have implicated the PKA
pathway as the mediator of anabolic bone growth.(7,18-20) Activation of PKA and PKC
lead to the phosphorylation of transcription factors like CREB which regulate
transcription of PTH target genes, involved in bone formation.(21)
To determine the structural requirements for PTH binding to PTH1R in kidney
and bone, various peptide analogues were designed. Many studies were undertaken in the
1970s to characterize the amino terminal end of the peptide, and several N-terminally
shortened fragments of bPTH were synthesized and assayed for biological activity. The
working hypothesis at that time was that amino acids 15-34 of PTH (1-34) were required
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for receptor binding, and the amino acid residues 1-14 were responsible for signaling
events after binding.(22-24) In addition, the bovine PTH analogue, [Tyr34] bPTH 7-34 was
synthesized as an antagonist to be used in clinical disorders of excess PTH.(25) This
analogue was further modified, [Trp12, Tyr34] bPTH (7-34) (PTH (7-34)) to increase
receptor affinity.(26) Interestingly, recent studies have shown that PTH (7-34) in HEK293
cells transfected with PTH1R activates extracellular signal-regulated kinase (ERK) in a
G-protein-independent and a β-arrestin-dependent manner, a response which was
temporally and spatially distinct from that produced by human PTH (1-34) (PTH (134)).(27) In addition, PTH (7-34) administered to mice was shown to increase bone
formation without the associated bone resorption seen with PTH (1-34).(28) The
mechanism leading to bone formation that is uncoupled from bone resorption has yet to
be identified. These data suggest that PTH (7-34) may be a potential anabolic agent since
it increases bone formation without resorption and may be used long-term. However, the
functional aspects of this peptide must be comparable to or better than the current drug on
the market, PTH (1-34). Studies performed in rats have shown that PTH (1-34) regulated
numerous genes (~1000), but the patterns of gene regulation differed depending upon
intermittent versus continuous administration of the peptide.(18) Another study compared
changes in mouse calvarial bone transcriptome of wild type and β-arrestin 2 -/- mice
treated with PTH (1-34) or PTH (7-34). These data demonstrated that the arrestin
pathway-selective ligand PTH (7-34) produced a transcriptome signature with limited
overlap to that produced by PTH (1-34), suggesting that bone-forming effects of the two
ligands are achieved through markedly different mechanisms of action,(29) including the
ability to modify β-arrestin2 based pathways.
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The effect of the PTH (7-34) on in vivo bone formation in humans has not been
examined, nor has its effects been assessed on human osteoblasts in vitro. Furthermore,
there have been no studies assessing the impact of PTH (1-34) and PTH (7-34) in
combination in any osteoblast model. The increase in bone formation demonstrated upon
PTH (7-34) administration to mice was not associated with resorption.(28) Since this
peptide was administered on a background of endogenous PTH, it is not clear if this
reflects an independent effect of PTH (7-34) or a modification of the response to
endogenous PTH. To address this possibility, we examined the relationship of the two
peptides in vitro using the human Saos2 osteosarcoma cell line from which the PTH1R
was cloned.(30) We have examined the effect of each peptide, alone and in combination,
on second messenger production, pro-proliferative kinase signaling, and on cell
proliferation and survival signals. We also assessed the impact of the two peptides on the
expression of selected genes related to bone formation and remodeling. These data
demonstrate that presence of peptides together produces signals distinct from individual
peptides, resulting in different cellular responses.
Materials and methods
Materials
Synthetic hPTH (1-34) and bPTH(D-Trp12, Tyr34)7-34 (PTH (7-34)) were purchased
from Bachem, Torrance CA. Forskolin was obtained from Tocris (Bristol, UK), while 3isobutyl-1- methylxanthine (IBMX) and bovine serum albumin (BSA) were from Fisher
Scientific (Waltham MA). Dulbecco’s phosphate buffered saline (DPBS) was purchased
from Cellgrow, (Manassas, VA), fetal bovine serum (FBS) was from Gibco,
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Thermofisher (Grand Island, NY) and protease inhibitor cocktail from Pierce (Rockford
IL.)
Cell culture
Saos2 cells were purchased from American type culture collection (ATCC, Manassas,
VA) and were plated at a density of 50,000 cells/ml in T25 or T75 cell culture flasks.
Cells were grown in DMEM (Corning, Corning NY), supplemented with 10% FBS
(Gibco, Grand Island, NY),100 U/ml of penicillin, and 100 µg/ml of streptomycin
(Cellgrow, Manassas, VA), and incubated at 37C in 5 % CO2. Medium was changed
every 2-3 days and cells were passed when confluent using 0.025 % trypsin containing
0.01% EDTA in Hank’s balanced salt solution (HBSS, Corning, Corning NY).
Calcium assay
Intracellular calcium mobilization was measured using the FluoForte® Calcium Assay kit
for microplates (Enzo Lifesciences, Farmingdale NY) according to the manufacturer’s
instructions. Briefly, Saos2 cells were plated at 60,000 cells/well in a 96 well plate with
clear bottoms and black walls (Corning, Corning NY). Twenty-four hours later, the
medium was removed and cells were washed twice with DPBS to remove residual phenol
red from the medium. The dye-loading buffer and a quencher (0.004% hemoglobin in
100 mM sodium phosphate buffer, pH 7.0) were added to minimize background
fluorescence and cells were incubated for 1 hour at room temperature. After the
incubation period, cells were treated with the calcium ionophore ionomycin, the cagedcalcium- chelator EGTA, or increasing concentrations of PTH (1-34), PTH (P-734), or
increasing concentrations of PTH (1-34) +1 µM PTH (7-34). The caged-calcium chelator
EGTA was activated by UV light at 355 nm using a BioTek Synergy H1 plate reader. At
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each concentration, a vehicle control (DPBS with 0.1% BSA) was also assayed. The
kinetics of calcium release were captured using a BioTek Synergy H1 plate reader with
fluorescence read at excitation 490 nm /emission 525 nm. The average of the maximum
fluorescence value of quadruplicate reads for each concentration of the agent was
calculated. The data were plotted as means ± SEM of percent basal relative fluorescence
for three independent experiments.
cAMP assay
Saos2 cells were plated in 48-well plates at a density of 100,000 cells/ml in DMEM
supplemented 10% FBS, 100 U/ml of penicillin, and 100 µg/ml of streptomycin. Medium
was changed to DMEM with 0.5% serum for 18-20 hours and then treated with PTH (134) and PTH (7-34) for 5 minutes in the presence of the phosphodiesterase inhibitor
IBMX (1 mM). All dilutions were made in medium containing IBMX. Cell culture
medium was aspirated and agents were added to a final volume of 200 µl per well, then
incubated at 37C for five minutes. The treatment was stopped by aspiration of the media
from the wells and adding 0.1N HCl (125 µl/well) to lyse the cells. The plates were spun
at 1000 x g for 5 minutes, and the supernatant was removed and assayed for cAMP using
the cAMP-EIA kit (Cayman, Ann Arbor MI) as per manufacturer’s instructions. Plates
were read at 405-420 nm. The data are calculated as pmol cAMP/ml and reported as
means ±SEM for three independent experiments assayed in triplicate.
Cell Proliferation assay
Saos2 cells were plated at 5,000 cells/well in 96 well clear bottom black walled plates
(Corning, Corning NY). The next day, the medium was removed and replaced with
medium containing 0.5 % FBS. Increasing concentrations of PTH (1-34), PTH (7-34), or
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increasing concentrations of PTH (1-34) +1 µM PTH (7-34) were added to the wells.
The plates were incubated at 37C for 24 h and cell number was determined using
FluoReporter® Blue Fluorometric ds DNA quantification kit (Molecular Probes,
Carlsbad CA) as per manufacturer’s instructions. Fluorescence was read at excitation 346
nm /emission 460 nm, and cell number was determined from a standard curve plated at
the same time. Data are reported as mean ±SEM of the fold change over basal cell
number and represent three independent experiments assayed in triplicate.
Growth curves
Saos2 cells were plated at 5000 cells/well in a 96 well clear bottom, black walled plate
(Corning, Corning NY). The next day, the medium was removed and replaced with
medium containing 0.5 % FBS. Increasing concentrations of PTH (1-34), PTH (7-34) or
increasing concentrations of PTH (1-34) +1 µM PTH (7-34) were added to the wells and
the plates were incubated at 37C for 6 days. During the 6 days of incubation, cell
number was measured at 24 h intervals, at 24, 48, 72, 96, 120 and 144 h. Medium was
removed at each time point and the plate was frozen at -80C. Cell number was measured
for all plates using FluoReporter® Blue Fluorometric ds DNA quantification kit
(Molecular Probes, Carlsbad CA) as per manufacturer’s instructions. Fluorescence was
read at excitation 346 nm/emission 460 nm and cell number was determined from a
standard curve plated at the same time. Data are reported as mean ± SEM of the fold
change over basal and represent three independent experiments assayed in triplicate.
Caspase 3 Apoptosis assay
Saos2 cells were plated in 6-well plates at a density of 75,000 cells/ml (Corning, Corning
NY). On day 3, the medium was removed and replaced with medium containing 0.5 %
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FBS or 10% FBS. PTH (1-34) at 1 and 100 nM, PTH (7-34) at 1 µM and PTH (1-34)
(100 nM) + PTH (7-34) (1 µM) were added to the wells. The plates were incubated at
37C for 24 h. Spent media was collected and spun to collect floating cells, which were
extracted on ice for 30 minutes with radioimmunoprecipitation assay (RIPA) buffer (150
mM sodium chloride, 50 mM Tris pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS) containing a protease inhibitor cocktail (aminoethyl benzene sulfonyl fluoride HCl,
Aprotinin, Bestatin, E64 N-(trans-epoxysuccinly)-L-leucine 4- guanidine butylamide,
Leupeptin, Pepstatin A), then centrifuged at 10,000xg for 15 minutes. Attached cells were
harvested by trypsinization and lysed with RIPA buffer containing protease inhibitor on
ice for 30 minutes, then centrifuged at 10,000xg for 15 minutes. The supernatant from
both steps was collected, pooled, and protein determination was performed using the
Lowry assay.(31) Apoptosis was measured using EnzChek® Caspase 3 Assay Kit #2
(Molecular Probes, Carlsbad CA) as per manufacturer’s instructions using 15 µg of
protein per sample. Fluorescence was read at excitation 490 nm/emission 525 nm. Data
are reported as mean ± SEM of the fold change over basal and represent three
independent experiments assayed in triplicate.
Phospho-antibody cell based ELISA (PACE)
Cells were grown in 96-well plates until confluent, then serum- deprived in DMEM
containing 0.5% serum for 18-20 h before the assay is performed. Cells were treated with
increasing concentrations of the peptide(s) for a defined time course as indicated in each
figure. After treatment is complete, activated ERK and activated Akt were determined as
previously described.(32) Briefly, cells were fixed in 4% formaldehyde in PBS, blocked in
5% non-fat milk in PBS containing 0.1 %Triton (PBS-T) for an hour at room
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temperature, incubated with primary antibodies for ERK (rabbit monoclonal antiphospho-p44/42 MAPK (Erk1/2) Thr202, Tyr204, 1:8000) or Akt (rabbit polyclonal antiphospho-Akt Ser473, 1:1000) both from Cell Signaling Technology (Danvers, MA) and
incubated at 4C overnight. Cells were washed with PBS-T then developed with an HRPcoupled goat anti-rabbit IgG (1:1000) (Cell Signaling, Danvers, MA) and incubated for
one hour at room temperature. Cells were washed 3X with PBS-T and 2X with PBS,
incubated with 1-step Ultra TMB-ELISA (Fisher Scientific, Waltham MA) then stopped
with 2 M sulfuric acid. The plates were read on a BioTek synergy H1 plate reader at 450
nm. After reading, plates were washed twice with distilled water, air-dried, then stained
in 0.04% crystal violet in 4% ethanol for 1 hour at room temperature to quantify attached
cells. The cells were then solubilized with 1% SDS for 1 hour at room temperature and
plates were read at 595 nm for normalization. Data are reported as mean ±SEM of the
fold change over basal and represent three independent experiments assayed in triplicate.
RNA isolation
Total RNA was isolated from Saos2 cells grown in 6-well plates at 75,000 cells/ml. On
day 3, the medium was removed and replaced with medium containing 0.5% serum. PTH
(1-34) at 100 nM, PTH (7-34) at 1 µM and 100 nM PTH (1-34) + 1 µM PTH (7-34) were
added to the wells. At 2 and 24 h, medium was removed, cells were trypsinized using
0.025% trypsin containing 0.01% EDTA in HBSS (Corning, Corning NY), centrifuged,
and the pellet was either frozen at -80C or processed immediately for RNA isolation
using RNeasy kit (Qiagen, Germantown, MD) following manufacturer’s instructions.
Total RNA was eluted from the column in 30 µl of RNase- free water. RNA
concentration and purity were measured using a Nanodrop ND1000 (Thermo Scientific,
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Waltham MA). Ratios of absorbance at 260 nm /280 nm were between 1.8-2.0,
indicating minimal protein contamination, while 260 nm/230 nm were greater than 1.7,
indicating minimal organic contamination. Isolated RNA was stored at -80C until
further processing.
cDNA synthesis
Isolated RNA was used to synthesize cDNA using RT2 First Strand cDNA Synthesis Kit
(Qiagen, Germantown, MA) following manufacturer’s instructions in a BioRad iCycler
thermocyler. Briefly, genomic DNA was eliminated by mixing 0.5 µg of RNA and 2 µl
of buffer genomic elimination brought up to a final volume of 10 µl with RNase-free
water. These genomic DNA mix tubes were incubated at 42C for 5 minutes, after which
they were immediately placed on ice. The reverse transcriptase (RT) step was carried out
by making 10 µl of RT mix containing 4 µl of 5X buffer BC3, 1 µl of control P2, 2 µl of
RE3 RT mix, 3 µl of RNase-free water. 10 µl of RT mix was added to each 10 µl
genomic DNA elimination mix and was mixed gently by pipetting up and down. These
samples were incubated at 42C for 15 minutes, and then the reaction was stopped at
95C for 5 minutes. 91 µl of RNase free water was added to each tube and was gently
mixed by pipetting up and down to achieve a final volume of 111 µl of sample. The
samples were stored at -80C until processed for real time PCR.
Real-Time PCR
Custom plates with 12 genes related to bone formation and remodeling were selected
(Table 1) and ordered from SA Biosciences, Germantown MA. RT2 SYBR Mastermix
was purchased from Qiagen, Germantown MA. A Biorad CFX 96 thermocycler (Biorad,
Hercules, CA) was used to run the 96 well custom plates based on the cycling parameters
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indicated in the Array Handbook. 0.5 µg of RNA isolated was used to synthesize cDNA
using the RT2 First Strand Kit, and this was used to carry out qRT-PCR for the genes of
interest. Briefly, 25 µl of the PCR mix was added to each well of the RT2 PCR array
plate. Plates were tightly sealed and centrifuged for 1 minute at 1000 x g at room
temperature to remove bubbles. PCR cycling was programed to 10 minutes at 95C to
activate HotStart DNA Taq polymerase, followed by 40 cycles of amplification and
fluorescence data collection for 15 seconds at 95C and 1 minute at 60C. Gene
expression was calculated using the 2 (-ΔΔ CT) method and expressed as difference in fold
change over basal. Fold-change greater than 1 is reported as upregulation and when it is
less than 1, the negative inverse of the result is reported as down regulation. Threshold
cycle value (CT) over 35 is considered non-expressed or negative. The controls, positive
PCR controls (PPC), reverse transcriptase (RT) and genomic DNA controls (GDC) are
calculated and pass the specification indicated in the manufacturer’s handbook. A
representative amplification and melt curve are included in Appendix B.
Western Blotting
Saos2 cells were grown in 6-well dishes at 75,000 cells/ml and on day 3, the medium was
removed and replaced with medium containing 0.5% serum. Cells were treated with PTH
(1-34) at 1 and 100 nM, PTH (7-34) at 1µM and 100 nM PTH (1-34) + 1 µM PTH (734). The plates were incubated at 37C for 24 h. At 2 and 24 h, medium was removed,
cells were trypsinized, lysed on ice for 30 min with RIPA buffer containing protease
inhibitors, and then centrifuged at 10,000 x g for 15 minutes. The supernatant was
collected, and protein determination was performed using the Lowry assay.(31) 15 µg of
protein was resolved on 12% SDS-PAGE, transferred to nitrocellulose, and proteins of
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interest were detected by incubating with primary antibodies against CDKN1A ( rabbit
monoclonal, 1: 1000), BCL-2 (rabbit polyclonal, 1:1000), and c-FOS (rabbit monoclonal,
1:500) from Cell Signaling Technology (Danvers MA), RANKL (mouse monoclonal, 2
Table 1. Gene List

Gene

Function and rationale

Osteoblast specific
osteoblast-specific transcription factor essential for osteoblastic
Runx2
differentiation
non-collagenous protein present in bone matrix involved in bone
Osteocalcin
remodeling
OPG
Osteoblast secreted protein and inhibits osteoclast formation since it is
(TNFSF11) a decoy receptor for RANKL
binds to OPG secreted by osteoblast, and RANK expressed on
RANKL
osteoclast precursor and is a key factor in osteoclast differentiation and
(TNFSF11b)
activation
Growth factors or growth related
Cyclin-dependent kinase1 inhibitor binds to and inhibits cyclin
CDKN1A
dependent kinase 2/4 and functions as a regulator of cell cycle
progression at G1 phase
Bcl-2
Integral outer mitochondrial protein that blocks apoptosis
Growth factor, osteogenic in nature. Induces cartilage and bone
BMP2
formation
Growth factor promotes osteoblast proliferation, survival and
IGF-1
differentiation
Transcription factors, extracellular matrix protein and the receptor
Immediate early gene, and a member of leucine-zipper family of
Fos
transcription factors
CREB1
Transcription factor, regulates osteoblast specific genes
PTH1R
Parathyroid Hormone Receptor binds PTH and is responsible for
calcium homeostasis.
Col1A1

Type I collagen is the most abundant ECM protein in the bone

Abbreviations: Runx2=runt related domain, OPG=osteoprotegerin, RANKL=receptor
activator of nuclear factor k B ligand, CDKN1A=cyclin dependent kinase inhibitor 1A,
Bcl-2= B-cell CLL/ lymphoma 2, BMP2=bone morphogenic protein 2, IGF-1=insulin–
like growth factor1, CREB1=cAMP dependent response element binding protein,
PTH1R=parathyroid hormone receptor, Col1A1=collagen 1A1
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µg/mL), and PTH1R (mouse monoclonal, 2 µg/mL) from R&D systems (Minneapolis,
MN), and RUNX2 (mouse monoclonal, 1:1000) from Millipore (Temecula, CA )
overnight at 4C. Blots were incubated with species-specific secondary antibodies
conjugated with HRP (1:1000; Cell Signaling Technology, Danvers, MA) at room
temperature for 1h. Chemiluminescence detection was performed using Super Signal®
West Pico from ThermoScientific (Rockford IL) and captured on a BioRad ChemiDoc™
Touch Imaging System. β-actin (mouse monoclonal, 1:40,000; Sigma St. Louis MO) was
used as a loading control. The blots were quantified using BioRad Image Lab Software
5.2.1. and were normalized to β-actin.
Data analysis
Data with reported EC50 values were calculated by non-linear regression analysis using
dose-response with variable slope model in GraphPad Prism (Version 5, La Jolla, CA).
All other data were analyzed in GraphPad Prism using 2-way ANOVA with Bonferonni’s
post-test. Data are considered significant when p is  0.05.
Results
Validation of intracellular calcium mobilization
The calcium assay was validated by measuring the changes in intracellular calcium, using
the calcium ionophore, ionomycin, and a caged-calcium chelator- EGTA. Ionomycin
rapidly increased intracellular calcium with a maximum effect appearing within 20
seconds as shown in Fig.1. Addition and activation of caged-EGTA abolished the
increase in intracellular calcium produced by ionomycin, demonstrating the sensitivity of
the assay to manipulations of calcium availability.
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Fig.1: Increase in intracellular calcium by ionomycin. Saos2 cells were grown to
confluency in 96 well clear bottom black walled plates. After 16-18 h, the medium was
removed and cells were loaded with calcium dye, a quencher, and treated with ionomycin
(Iono; 1 µM), EGTA (10 µM), or ionomycin + EGTA. Calcium mobilization was then
determined as described in Methods. The data are plotted as means ± SD from one
experiment assayed in quadruplicate.
Second messenger production by PTH peptides
To evaluate the ability of PTH peptides alone and in combination to activate the PTH1R,
we measured intracellular calcium mobilization and cAMP production in response to
each peptide. Saos2 cells were loaded with calcium- sensing dye and were then
stimulated with increasing concentration of PTH (1-34), PTH (7-34) or PTH (1-34) in the
presence of 1 µM PTH (7-34). PTH (1-34) caused a dose-dependent increase in
intracellular calcium with an EC50 of 5.8 x10-9 M (Fig. 2A). PTH (7-34) decreased effects
of PTH (1-34). In fact, PTH (7-34) increased potency of PTH (1-34) to 9.9 x 10-11 M.
Thus, PTH (7-34) behaves as an inverse agonist (lowering basal calcium) when used
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alone (Fig. 2B), but sensitizes Saos2 cells to calcium-mobilizing effects of PTH (1-34).
These data suggest that when both peptides are present, the calcium signal in these cells
is more robust and may have different consequences than with PTH (1-34) alone.
To assess the ability of PTH (1-34) and PTH (7-34) alone and in combination on
AC activation, Saos2 cells were stimulated with increasing concentrations of PTH (1-34),
PTH (7-34) or PTH (1-34) in the presence of 1µM PTH (7-34). PTH (1-34) produced a
dose-dependent increase in the production of cAMP with an EC50 of 1.2 x 10-11 M (Fig.
2C). In contrast, PTH (7-34) alone has no apparent effect, but competitively antagonized
the PTH (1-34) response, decreasing PTH (1-34)’s EC50 to 4.2 x 10-7 M. Closer
inspection of the PTH (7-34) response (Fig. 2D) revealed that it was an inverse agonist as
it lowers basal cAMP production. These data indicate that when both peptides are present
together, cAMP is not likely be the primary signaling pathway.
Changes in cell proliferation
Previous studies examining the effect of PTH (7-34) on bone in vivo suggested a role for
this peptide in promoting bone growth. One way to enhance bone formation is to increase
the number of bone-forming osteoblasts. To determine the effect of PTH (1-34) and PTH
(7-34) alone and in combination, on osteoblast cell number, we assayed DNA synthesis
in cell populations and correlated changes with cell number using a standard curve. Fig.
3A shows that a 24 h treatment with PTH (1-34) caused a dose-dependent increase in the
number of osteoblast present, a response completely blocked when cells were coincubated with 1 µM PTH (7-34). PTH (7-34) alone had no effect on cell number.
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Fig.2. Mobilization of intracellular calcium and activation of adenylyl cyclase by
PTH peptides. A) Saos2 cells were grown to confluence in 96 well clear bottom black
walled plates. After 16-18 h, the medium was removed and cells were loaded with
calcium dye, a quencher and challenged with increasing concentrations of PTH (1-34),
PTH (7-34), or increasing concentrations of PTH (1-34) with 1 µM PTH (7-34) (both).
Calcium mobilization was then determined as described in Methods. The data are the
means ± SEM for three independent experiments assayed in quadruplicate. B) PTH (734) behaves as an inverse agonist for calcium. C) Saos2 cells were plated in 48-well
plates, grown to confluence, and treated for 5 minutes with increasing concentrations of
PTH (1-34), PTH (7-34) or increasing concentrations of PTH (1-34) with 1 µM PTH (734) (both). Cells were then harvested and cAMP was measured as described in Methods.
PTH (1-34) dose-dependently increased cAMP production, a response competitively
antagonized by PTH (7-34). D) Closer examination of the PTH (7-34) dose-response
revealed that this peptide behaves as an inverse agonist. The data are plotted as means ±
SEM for three independent experiments assayed in triplicate.
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To determine if the PTH peptides affected Saos2 proliferation in a temporal
manner, we generated growth curves for a period of 6 days. We treated cells for 24 h and
then measured cell number at each concentration of PTH at 24 h interval over a period of
6 days. PTH (7-34) shows an increase in cell number between treatment days 3- 6 (Fig.
3B and appendix 3), but due to variability among the replicate data, these are not
statistically significant (p value for day 5 is 0.12). These data suggest that, although PTH

Fig.3. Effects of PTH peptides on Saos2 proliferation. Saos2 cells were plated in 96
well clear bottom black walled plates. After 16-18 h, medium was removed and replaced
with medium supplemented with 0.5% FBS. Cells were treated with increasing
concentrations of PTH (1-34), PTH (7-34) or increasing concentrations of PTH (1-34)
with 1 µM PTH (7-34) (both) and cell proliferation was determined as described in
Methods. A) After 24 hours, PTH (1-34) increased cell number while PTH (7-34) had no
effect alone and completely blocked the effect of PTH (1-34). B) Growth curves were
determined as described in Methods. Data from Day 5 shows an increase in cell
proliferation in response to PTH (7-34). The data are the means ± SEM for three
independent experiments assayed in triplicate. *, and ** indicate statistically different
from matched concentration of PTH (1-34), p  0.05 and p  0.01, respectively.

(7-34) effects are not significantly different from controls, PTH (7-34) responses may be
later appearing than PTH (1-34). However, the surprising finding is the loss of
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proliferation over the 6-day period with peptides in combination; the early increase seen
by PTH (1-34) after day 1 and late increase by PTH (7-34) at day 3-6 (Appendix 3).
This suggests a change in signal when both peptides are present together, and this change
is likely to be cAMP for PTH (1-34) as PTH (7-34) blocks cAMP production (Fig. 2).
Effect of PTH peptides on proliferative signaling
Our observation that PTH (1-34) increases cell number (Fig.3) led us to ask if the typical
pro-proliferative pathways, ERK and Akt, might be involved in this response. To address
this question, we measured peptide-dependent changes in ERK and Akt activities using
phosphoantibody cell based ELISAs. Fig. 4A shows the time course for high dose (100
nM) PTH (1-34), with a rapid and short-lived initial increase in ERK activity at 5 minutes
that declined to basal levels in 30 minutes. The increases at this time were dosedependent (Fig. 4B). There was a second rise at 120 minutes, although the changes were
not significantly different at any dose (Fig. 4B). In contrast, the time course for high dose
(1 µM) PTH (7-34) was different, with a modest increase at 5 minutes, followed by
sustained and significant increase from 30 to 60 minutes (Fig. 4A). The increases at
these times were significant only at 1 µM PTH (7-34) (Fig. 4C). Surprisingly, when cells
were incubated with both PTH peptides, ERK was not activated at any time or dose of
PTH (1-34) (Fig. 4D). Thus, although each peptide activated ERK when used alone, the
combination eliminated all changes in ERK activity. This lack of ERK activation may
reflect a change in receptor-generated signal, possibly cAMP, as PTH (7-34) eliminates
PTH (1-34)-induced cAMP production (Fig.2).
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Fig.4. Time and dose-dependent effect of PTH peptides on ERK activity. Saos2 cells
were treated with increasing concentrations of PTH (1-34), PTH (7-34) or increasing
concentration of PTH (1-34) in the presence of 1 µM PTH (7-34) (both). Plates were
incubated for the times indicated. Cells were washed and processed for ERK activation
by PACE as described in Methods. Treatment with A) highest doses of PTH peptides
produced peak ERK activity with distinct temporal patterns. B) PTH (1-34) increased
ERK activity at 5 minutes and later at 120 minutes. C) PTH (7-34) increased ERK
activity with peak effects between 30 and 60 minutes. D) Both peptides together
abolished the ERK activity peaks observed with PTH (1-34) and PTH (7-34)
individually. The data are the means ± SEM for three independent experiments. assayed
in triplicate. *, and ** indicates statistically significant from time matched basal, p  0.05
and p  0.01 respectively of PTH (1-34), PTH (7-34) and both together.

Fig. 5A shows the time course for low dose (0.01 nM) PTH (1-34) and (10 nM) PTH (734) on Akt activity. Neither peptide had any effect at these low doses when used alone,
but Akt activity increased when both peptides were used together. PTH (1-34) dosedependently decreased Akt activity starting at 5 minutes and persisted for the duration of
the experiment (Fig. 5B). Although PTH (7-34) appeared to increase Akt activity (Fig.
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Fig.5. Time and dose-dependent effects of PTH peptides on Akt activity. Saos2 cells
were treated with increasing concentrations of PTH (1-34), PTH (7-34) or increasing
concentrations of PTH (1-34) in the presence of 1 µM PTH (7-34) (both). Plates were
incubated for the times indicated, then washed and processed for Akt activation by PACE
as described in Methods. Treatment with A) the lowest concentration of peptides plotted
show the distinct temporal pattern of Akt activation. B) PTH (1-34) decreased Akt
activity in a sustained manner from 5 to 120 minutes. C) PTH (7-34) had no effect. D)
Both peptides together resulted in an increase in Akt activity at low concentrations of
PTH (1-34), while high concentrations decreased Akt. The data are the means ± SEM for
three independent experiments assayed in triplicate. * and ** indicates statistically
significant from time-matched basal, p  0.05 and p  0.01 respectively of PTH (1-34),
PTH (7-34) and both together.

5C), it was not significant at any time point. Interestingly, when Saos2 cells were treated
with low doses of PTH (1-34) (10-11 to 10-9 M) in the presence of 1 µM PTH (7-34) Akt
activity was elevated, while PTH (7-34) plus high doses of PTH (1-34) (10-8, 10-7 M) led
to decreased Akt activity (Fig. 5D). These data suggest that a signal at low concentrations
of PTH (1-34) in the presence of 1 µM PTH (7-34), is responsible for this Akt activation,
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and this could be the calcium signal. However, increases in osteoblast cell number seen
with PTH (1-34) cannot be attributed to Akt since there is no activation of Akt
throughout the experiment.
Effects of PTH peptides on caspase-3 activity
Previous studies examining the effect of PTH (1-34) on bone in vivo and in vitro have
demonstrated a decrease in apoptosis as a mechanism for increased bone mass (33,34). Our
observation that low concentrations of PTH (1-34) in the presence of 1 µM PTH (7-34)
prevented the PTH-induced decrease in Akt activity led us to examine the effects of these

Fig.6. Effect of PTH peptides on caspase 3 activity. Saos2 cells were treated with 1 or
100 nM PTH (1-34), 1 µM PTH (7-34) or 100 nM PTH (1-34) + 1 µM PTH (7-34) (both)
for 24h. Medium was collected and caspase 3 activity was measured as described in
Methods. The data are the means ± SEM for three independent experiments assayed in
triplicate. * indicates statistically significant from time matched basal in each group, p 
0.05.
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peptides on apoptosis. We measured caspase3 activity as the extrinsic and intrinsic
pathways converge on this enzyme. (35) Neither of the peptides alone nor in combination
affects caspase-3 activity in cells grown in medium supplemented with 10% serum
medium. However, switching the medium from 10 % FBS to 0.5 % FBS (low serum)
medium appears to promote pro-apoptotic signals with PTH (1-34) at 1 nM, but the data
are not significant (Fig.6). These data demonstrated that serum and peptide treatment
have no effect on caspase-3 activity.
Gene Expression
Numerous studies carried out in vitro and in vivo have demonstrated that PTH regulates
the expression of transcription factors, growth factors, cell differentiation factors,
extracellular matrix proteins, cell cycle regulators, and genes involved in bone
remodeling.(18,29,34,36-42) Beck et al.(43) used a gene array approach to profile gene
expression during differentiation of mouse calvarial MC3T3-E1 cells to an osteoblast-like
phenotype, in which differentiation involved withdrawal from cell cycle by day seven
(decreased cyclins expression), followed by matrix accumulation and mineralization. To
determine how PTH (7-34) affected gene expression in the presence of PTH (1-34), we
used a PCR array to assess the changes in 12 genes (Table 1) following early (2 h) and
late (24 h) exposure to PTH (1-34), PTH (7-34) and both peptides in combination. Saos2
cells were grown in proliferative medium and then treated for 2 or 24 h with high (100
nM) dose PTH (1-34), 1 µM PTH (7-34) or 100 nM PTH (1-34) + 1 µM PTH (7-34). At
2 and 24 h, all treatments led to a decrease in expression of Runx2, a transcriptional
modulator of osteoblast differentiation (Fig. 7A). RANKL is secreted by osteoblasts and
regulates formation of osteoclasts, and expression levels were not significantly affected
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by any treatment at 2 h. However, at 24 h, PTH (1-34) and PTH (1-34) in the presence of
PTH (7-34) significantly elevated RANKL, while PTH (7-34) alone had no effect
(Fig.7B). Expression of osteocalcin (BGLAP), an important component of extracellular
matrix and a late differentiation marker, was significantly decreased by PTH (1-34) at 2
h, while PTH (7-34) had no apparent effect. At 24 h, PTH (7-34) decreased osteocalcin
expression while the other treatments had no effect (Fig.7C). OPG is the decoy receptor
produced by osteoblasts to sequester RANKL and prevent it from binding to RANK on
the surface of the osteoclast and promote bone resorption. Expression of OPG was
significantly reduced by all treatments at 2 h, and at 24 h, except for cells treated with
PTH (7-34) alone. Interestingly, PTH (7-34) treatment was significantly different
between the two-time points (Fig.7D). This increase in RANKL with a decrease in OPG
at 24 h with PTH (1-34) is consistent with data(18) where PTH (1-34) is promoting bone
resorption. Presence of PTH (7-34) alone produced no change in RANKL and OPG
mRNA at 24 h suggesting that this peptide does not promote bone resorption.
Next, we assessed the expression of genes regulating growth. CDKN1A or p21Cip1
is a cyclin-dependent kinase inhibitor that binds to and inhibits activity of cyclindependent kinase 2 (cdk2) and cdk4. This inhibition of cdk2/4 results in blocking cell
cycle progression through G1/S phase of the cell cycle. p21Cip1 mRNA at 2 h was
significantly decreased in the presence of both peptides but not by either peptide alone.
At 24 h, PTH (1-34) and both peptides together significantly decreased expression, while
PTH (7-34) alone had no effect (Fig. 8A). These data are consistent with PTH (1-34)
promoting cell cycle progression. B-cell leukemia/lymphoma 2 (Bcl-2) is a proto
oncogene known to suppress apoptosis and may play an important role in increasing
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osteoblast number during anabolic actions of PTH.(33) Bcl-2 mRNA was significantly
decreased by all treatments at 2 h, and at 24 h by PTH (1-34) and both peptides together.
Cells treated with PTH (7-34) alone for 24 h had no effect on Bcl-2 mRNA levels
(Fig.B). Based on these data, Bcl-2 is not available for protection from pro-apoptotic
signals. Bone morphogenic protein2 (BMP2) is a differentiation factor capable of
inducing new bone formation. In contrast, PTH (7-34) inhibited BMP expression,

Fig.7. PTH peptide-induced changes in expression of osteoblastic genes. Saos2 cells
were plated in 6 well dishes and grown to confluence. Cells were treated with 100nM
PTH (1-34), 1 µM PTH (7-34) or both peptides (100 nM PTH (1-34) and 1 µM PTH (734)) for 2 and 24 h. RNA was isolated, and real-time PCR was performed using custom
arrays from SA Bioscience as described in Methods. A) Runx2 B) Rankl C) osteocalcin
D) OPG. The data are plotted as means ± SEM of three independent experiments assayed
in duplicate. * indicates significantly different from time-matched basal values, p  0.05
and # indicates different from the same 2h treatment, p  0.05.
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but did not affect the PTH (1-34) induced expression at either time. These data suggest
that BMP2 may have an indirect role in proliferation seen with PTH (1-34). Insulin-like
growth factor 1 (IGF-1) is secreted by osteoblasts and signals osteoblast proliferation,
survival, with expression levels varying based on osteoblast differentiation stage.

Fig.8. PTH peptide associated changes in expression of genes regulating growth.
Saos2 cells were plated in 6 well dishes and grown to confluence. Cells were treated with
100 nM PTH (1-34), 1 µM PTH (7-34) or both peptides (100 nM PTH (1-34) and 1 µM
PTH (7-34)) for 2 and 24 h. RNA was isolated, and real-time PCR was performed using
custom arrays from SA Bioscience as described in Methods. A) p21cip1 B) Bcl-2 C)
BMP2 D) IGF-1. The data are plotted as means ± SEM of three independent experiments
assayed in duplicate. * indicates significantly different from time-matched basal values, p
 0.05 and # indicates different from the same 2h treatment, p  0.05.

Expression of IGF-1 at 2 h was significantly decreased with PTH (1-34), while other
treatments had no effect. There was no effect at 24 h with any of the treatments; however,
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PTH (1-34) was significantly different between the time points, as seen in Fig.8D. These
data indicate that IGF-1 is not likely to be playing a proliferative role in Saos2 cells under
these experimental conditions.
The third group of genes assessed consists of transcription factors (c-fos and
CREB1), the extracellular matrix protein collagen 1A1 (COL1A1), and the PTH
receptor (PTH1R) (Fig. 9). c-fos is an immediate early gene that has been implicated as
a regulator of cell proliferation, differentiation, and transformation. Fig.9A shows no
significant change in c-fos mRNA with any treatment group. At 24 h, c-fos mRNA was
decreased in PTH (7-34)-treated cells, and these data imply that c-fos is not regulating
the expression of bone remodeling genes like collagenase 3. PTH1R mRNA expression
was not affected by any treatment at 2 h, but was significantly decreased by all
treatments at 24 h (Fig. 9B). This is not surprising, as prolonged exposure to receptor
ligands like PTH typically leads to downregulation of PTH1R mRNA and protein
(Appendix D). The cyclic AMP response element binding protein (CREB1) is a
transcription factor that binds to the cAMP response element (CRE) of a target gene for
regulation. Fig.9C demonstrates that all treatments resulted in a significant reduction in
CREB1 mRNA at 2 h, while PTH (7-34) alone and both peptides together sustained this
reduction at 24h. These data suggest that CREB1 is not regulating c-fos, Runx2 and
BMP2 genes. The last gene assessed was Col1A1 which encodes type 1 collagen, the
most abundant protein found in extra cellular matrix of the bone. Col1A1 mRNA was
significantly decreased at 2 h in the presence of PTH (1-34), but PTH (7-34) alone had
no effect (Fig.9D). At 24 h, Col1A1 expression was reduced in all treatments,
suggesting that cells are in proliferative and not differentiation stage.
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Fig.9. PTH peptide-induced inhibition of transcription factors, collagen 1A1 and
the PTH1R. Saos2 cells were plated in 6 well dishes and grown to confluence. Cells
were treated with 100 nM PTH (1-34), 1 µM PTH (7-34) or both peptides with 100 nM
PTH (1-34) and 1 µM PTH (7-34) for 2 and 24 h. RNA was isolated, and real-time PCR
was performed using custom arrays from SA Bioscience as described in methods. A) cfos B) PTH1R C) CREB1 D) Col1A1. The data are plotted as means ± SEM of three
independent experiments assayed in duplicate. * indicates significantly different from
time-matched basal values, p  0.05.
Discussion
The human skeleton must grow, repair, and maintain over a lifespan. Bone is
continuously being resorbed and rebuilt at about 1-2 million sites per adult skeleton.(44)
Resorption is carried out by hematopoietically-derived osteoclasts, which take about 3
weeks per site to resorb bone. New bone is formed by osteoblasts, which have a
mesenchymal origin and take between 3-4 months to form new bone. In a healthy adult,
there is balance between osteoblastic bone formation and osteoclastic bone resorption, a
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balance that is skewed towards osteoclasts and bone resorption as we age. This increase
in bone resorption results in osteoporosis, which leads to frailty of bones and
susceptibility to fractures such that for every 10% of bone that is lost, the risk of fracture
doubles.(44) Traditionally, drug treatments for osteoporosis have been designed to prevent
resorption. These drug treatments include; the use of bisphosphonates, which inhibit
osteoclastic bone resorption, long-term estrogen therapy that is antiresorptive, the use of
selective estrogen receptor modulators (SERM) that act as estrogen agonists in bone but
as antagonists in breast and uterus, and calcitonin, which blocks osteoclast activity. (45) It
has been well-established that PTH (1-34) increases bone formation, but long- term use
results in the reappearance of its bone-resorbing properties. The only anabolic bone
formation drug on the market is rhPTH (1-34) or teriparatide (Forteo®), that was
approved in 2002. However, this drug cannot be administered for more than 2 years over
a life span, which limits its usefulness to treat a growing population of aged patients.(14)
There has been a need for a PTH peptide that promotes bone formation and can be used
long- term to address the needs of osteoporotic patients. Recent work has identified bPTH
(7-34) as a potentially useful therapeutic agent based on its apparent ability to increase
bone formation.(28,29) Bovine PTH (7-34) was initially designed as an antagonist(25) to
combat hyperparathyroidism and was further modified to increase its affinity to
receptor.(26) Recent studies have shown that bPTH (7-34) can behave as an inverse
agonist, and as a biased agonist depending on the animal model and cell line
examined.(27,46-48) In HEK cells transfected with PTH1R, Gesty-Palmer et al.(27) showed
that bPTH (7-34) can recruit β-arrestin2 and signal through ERK in a manner temporally
and spatially distinct from that of PTH (1-34). Furthermore, they showed in an in vivo
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mouse model that bPTH (7-34) increased bone formation without associated bone
resorption, essentially un-coupling the two processes, a response not observed with PTH
(1-34).(28) In contrast, bPTH (7-34) did not increase bone formation in
parathyroidectomized rats(47), suggesting that bPTH (7-34) may not be capable of
increasing bone formation in all animal models, or that it may require endogenous PTH.
In the in vivo study using mice, the anabolic effects of bPTH (7-34) were observed on a
background of PTH (1-34), and thus the data could reflect modification of the
endogenous PTH and not the effect of bPTH (7-34) alone. In addition to the contrasting
effects of PTH (7-34) in mice and parathyroidectomized rats, to our knowledge, no
studies of the effects of PTH (7-34) alone, and in the presence of PTH (1-34), have been
performed on human osteoblasts. Thus, we wanted to investigate the activation of
signaling pathways and downstream events when PTH (1-34) and bPTH (7-34) are added
individually or together in a human Saos2 osteosarcoma cell line, from which the PTH1R
was initially cloned.(30)
Measurement of cAMP has been a classical biological assay to demonstrate
activation of Gαs-AC coupled GPCRs.(49) Our data show that PTH (1-34) stimulates the
production of cAMP with an EC50 of 10-11 M, showing a high affinity coupling of the
PTH1R to AC activation, similar to work done by others in rat sarcoma and primary rat
calvarial cells.(16,50,51) Other studies performed in Saos2 cells have demonstrated an EC50
of 10-9 M(52) and 10-8 M.(53) The higher EC50 for cAMP in our study compared to others
in the same cell line likely reflects different experimental conditions including cell
culture conditions, assay temperature, lack of PDE inhibitors, and cAMP assay methods.
As previously shown,(54) PTH (7-34) competitively antagonizes PTH (1-34)-dependent
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cAMP production. Interestingly PTH (7-34) lowered basal cAMP, indicating it was an
inverse agonist consistent with reports by other investigators.(27,46) In HEK293
expressing constitutively active PTH1R, PTH (7-34) is an inverse agonist for cAMP,(27)
but in rats,(25) bovine renal cortical membranes,(26) and in U2OS and CHO cells
transfected with PTH1R,(48) it has no effect when administered alone, but is a competitive
antagonist in the presence of PTH (1-34). These data indicate that constitutive activity of
the receptor is required for inverse agonist properties, suggesting that PTH1R in Saos2
cells are constitutively active. PTH (1-34) stimulates the mobilization of intracellular
calcium in a dose-dependent manner similar to others studies(55,56) with an EC50 of 5.8 x
10-9 M. These data are comparable to EC50 values reported in mouse distal convoluted
tubule,(57) fetal rat bone,(58) and Saos2 cells.(59) PTH (7-34) does not increase
intracellular calcium but does increase the potency of PTH (1-34) when both are present.
In contrast, Friedman et al.(57) showed that PTH (7-34) competitively inhibited the
calcium response of PTH (1-34) in mouse distal convoluted tubule. It seems likely that
this difference reflects both species (human vs rat) and cell type (kidney vs bone). In our
system, PTH (7-34) sensitizes Saos2 cells to calcium-mobilizing effects of PTH (1-34).
This novel effect of PTH (7-34) may reflect the ability of PTH (7-34) to antagonize
cAMP production, since PTH (7-34) effectively abolishes PTH (1-34)-dependent cAMP
at concentrations less than 10-9 M, even in the presence of IBMX. This loss of cAMP
may relieve a suppressive effect of cAMP in calcium signal. cAMP and its effectors can
modulate cyclic nucleotide gated channels, ryanodine receptor 2 (RYR2), L-type calcium
channels, plasma membrane calcium ATPase channel (PMCA), and sodium-calcium
exchanger (NCX).(60) Osteoblasts have calcium efflux channels, PMCA and NCX,(61) and
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it has been shown that PKA activates these efflux channels through phosphorylation in
mouse acinar cells(62) and human neuroblastoma cells,(63) resulting in a rapid clearance of
intracellular calcium. It is probable that in the presence of both peptides, when cAMP
production is blocked, that the efflux channels are not activated, resulting in an increase
in intracellular calcium.
The anabolic effects reported for PTH (1-34) and PTH (7-34) suggested that we
should see changes in cell number following exposure to these peptides. In fact, a 24 h
treatment with PTH (1-34) produced a dose-dependent increase in DNA synthesis, while
PTH (7-34) had no effect. When both peptides were present together, the proliferative
effect of PTH (1-34) was abolished. The data with PTH (1-34) are comparable to those in
other bone models, where cell proliferation was measured as cell number and/or DNA
synthesis including mouse radii,(64) human trabecular bone,(65) rat calvariae,(66) the TE85
human osteoblast precursor cell line,(67) and bone marrow stromal cells.(68,69) PTH (1-34)
also stimulates cell proliferation in human chondrocytes,(70) human periodontal ligament
cells,(71) and human pediatric chondrocytes.(72) Compared to PTH (1-34), there is limited
data on effects of PTH (7-34) on cell proliferation. It was shown that PTH (7-34)
increases human epidermal cell proliferation,(73) while it inhibits primary mouse
osteoblast cell proliferation.(29) In our in vitro study, we did not see an increase in DNA
synthesis, and these data are similar to data from mouse primary osteoblast cells,(29)
where there was either a decrease or no effect on proliferation with this peptide. Data
from our growth curves demonstrated that PTH (1-34) increased DNA synthesis at 24 h,
while PTH (7-34) showed a trend in increasing DNA synthesis starting at day 2 that
lasted until day 5. However, co-incubation with both peptides had no effect on DNA
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synthesis throughout the time course of 6 days. These data suggest that individually, PTH
(1-34) and PTH (7-34) regulate DNA synthesis in a temporally distinct manner but when
present together, the proliferative effects of PTH (1-34) are lost. Since cAMP is
eliminated when the two peptides are present together, it suggests the growth-promoting
effects of PTH are cAMP-dependent response, consistent with observations by Partridge
et al.(18) If Saos2 cells response reflects the effects of these peptides in vivo, it seems
unlikely that anabolic responses to PTH (7-34) reflect an increase in cell number.
To identify the pro-proliferative signaling molecules, we examined the activation
of pro-mitogenic ERK and pro-survival Akt. Similar to reports by Gesty-Palmer et al.,(27)
we show a rapid increase in ERK activity with PTH (1-34) at 5 minutes that declines to
basal by 30 minutes with a second rise at 120 minutes. It has been well-established that
cAMP-PKA and PKC pathways can activate ERK1/2, and since ERK1/2 plays a central
role in cell proliferation; (74,75) it seems PTH (1-34)-dependent ERK activation is through
cAMP, as ERK activation is lost when both peptides are present together. PTH (7-34)
also increases ERK activity, but this is temporally distinct from PTH (1-34), with a late
and sustained peak at 30 minutes that lasts for the duration of the time course, a response
comparable to that reported by Palmer et al.(27) PTH (7-34) has been shown to activate
ERK1/2 in a G-protein-independent and a β-arrestin-dependent manner,(27) and this is
most probably how ERK is activated by PTH (7-34) in Saos2 cells, since neither cAMP
nor calcium are increased when this peptide is added alone. However, when both peptides
are present together, the ERK activity seen with either of the peptides individually is
abolished. The lack of ERK signal with both peptides was unanticipated and could be due
to differences in proximal signaling of the peptides alone and together. Both peptides
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together result in loss of cAMP and sensitization of the calcium signal, and these could be
responsible for loss of ERK activity. There is substantial data in the literature for calcium
inhibition of the Ras/Raf/MEK/ERK pathway.(76-78)
Although it seems likely that cAMP-dependent ERK activation mediated the
proliferative response to PTH (1-34), we also assessed the possibility that the activation
of Akt, a pro-survival signal might contribute. Phosphorylated Akt was decreased in a
sustained manner by PTH (1-34) from 5 minutes to 60 minutes, while PTH (7-34) caused
no change at any time. However, when both peptides are present together, there is an
increase in Akt activity with low dose (0.01nM) of PTH (1-34) at early time points of 15
and 30 minutes and a decrease with high dose, which was sustained throughout the time
course. This increase in Akt activity suggests a correlation with increased intracellular
calcium seen when both peptides are present together. Akt is not mediating proliferation,
as there is no increase in cell number at 24 h in cells treated with both peptides. However,
to our knowledge, these data with an increase in Akt activity in cells treated with both
peptides is a novel observation. While we believe that the loss of cAMP/sensitization of
Ca signaling leads to the loss of ERK activity in cells treated with both peptides, cross
talk between ERK and Akt could also be responsible. Pharmacological inhibition of ERK
in human and mouse primary cells produced an increase in Akt through a calciumdependent manner.(79) ERK was inhibited by Akt via direct phosphorylation and
inhibition of Raf-1 in rats.(80) And, Akt-phosphorylated FOXO1 binds to a GAP
(IQGAP1) (IQGAP1 acts as a scaffolding molecule for assemblage of MEK-ERK) and
impedes phosphorylation of ERK1/2 in human cancer cells.(81) Therefore, it is feasible
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that the cross talk between ERK and calcium, and/or ERK and Akt are responsible for the
total loss of ERK in the presence of both peptides.
Our data with Akt led us to examine the effect of these peptides on the activity of
caspase-3, an indicator of apoptosis. Increase in capase-3 activity would indicate cell
death resulting in a low cell number. After 24 h in low serum conditions, we observed an
increase in caspase-3 activity with 1nM of PTH (1-34) and these data roughly correlate
with a sustained decrease in phosphorylated Akt during the two hour time course with
PTH (1-34). This increase in caspase-3 activity could be due to serum deprivation of
cells wherein the cells are predisposed to apoptosis compared to non-serum deprived.
These data demonstrate that Akt is not playing a pro-survival role since its activity is
decreased with PTH (1-34) and was not changed by treatment with PTH (7-34).
A number of studies have utilized changes in gene expression profiles to provide
insights into the differing effects of PTH (1-34) and PTH (7-34) on osteoblast function.
We assessed the expression of 12 genes and categorized them into transcription factors
(Runx2, c-fos, CREB1), pro-differentiation (osteocalcin, col1A1), pro-proliferative (Bcl2, p21cip1, BMP2, IGF-1), bone-remodeling (RANKL, OPG), and the PTH1R.
PTH (1-34) produces changes in gene expression consistent with a proproliferative state, as the markers of osteoblast differentiation are suppressed in PTH (134) treated cells. These changes include a reduction in expression of Runx2, osteocalcin,
and ColA1. These data are consistent with other studies showing that PTH reduces the
expression of Runx2 in MC3T3 cells,(82) HeLa, human OB-6 and primary mouse calvarial
cells,(34) and murine-derived bone-marrow stromal cells.(83) The osteocalcin data are
supported by studies in ROS 17/2.8 cells,(84) and rats.(18) Likewise, the reduced
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expression of Col1A1 is comparable to those of Kream B et al.,(40) where PTH reduced
collagen mRNA in rats, UMR 106 cells,(85) and mouse calvariae.(86) PTH increased
CREB at the post-translational level (36) by phosphorylation and this is a rapid event
occurring between 15 and 30 min.(34) In our study, we did not see an increase in
expression of CREB1, and it is possible that we may have missed this activation of
CREB due to our longer treatment time-period. Previous work performed in in vitro and
in vivo has demonstrated an increase in c-fos expression in a transient and rapid manner
(within 60 min) in UMR 106,(87-89) MC3T3 cells,(90) and rats.(91,92) mRNA levels from 2 h
in our experiments showed no change from basal levels; however, protein data at the
same time point show an increase (Appendix D). This disparity in protein levels
compared to mRNA could be explained by the inherently short-lived c-fos protein, which
is stabilized by post-translation phosphorylation through ERK.(93) In our study PTH (134) increases BMP2 and reduces p21cip1, suggesting a proliferative effect consistent with
its ability to increase DNA synthesis. Multiple preclinical studies conducted in primates
and other mammals have proven BMPs to be effective in restoring large segmental bone
defects (94) and if PTH peptides were promoting bone growth, we would expect an
increase in BMPs. A decrease in p21cip1will allow cells to progress through the G1/S
phase of the cell cycle and lead to cell proliferation.(74) We expected an increase in the
bone remodeling marker RANKL, with a decrease in OPG, which implies a potential for
bone resorption in support to similar data reported by Partridge and Palmer.(18,29,39) In
contrast, the PTH (7-34) gene profile suggests pro-differentiation due to lack of
suppression in differentiation markers of osteocalcin and Col1A1 at the early time point
of 2 h, and no change in proliferative markers like BMP2 and p21cip1. Expression data for
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Runx2, CREB1 and c-fos are similar to PTH (1-34) except there is no increase in c-fos
protein (Appendix D). RANKL is not increased with PTH (7-34) treatment indicating
that this peptide will not couple bone formation and bone resorption while PTH (1-34)
will. However, when both peptides are present together, the overall profile reflects that of
PTH (1-34), suggesting that it may be pro-proliferative but has the potential to increase
bone resorption. All treatments decreased the expression of PTH1R mRNA and protein
(See Appendix D) and indicate that the receptor has been downregulated as reported in
other studies.(95)
Overall our gene data shows that RANKL, OPG, p21cip1, and BMP2 are
differentially regulated by PTH (1-34) and PTH (7-34) alone, while the combination of
both peptides results in expression pattern similar to PTH (1-34) alone. Therefore, use of
PTH (7-34) in vivo on a background of endogenous PTH (1-34) may not promote bone
formation due to one of two reasons; first, PTH (7-34) has a much lower affinity for the
PTH1R compared to PTH (1-34).(96) If this lack of response simply reflects differences
in affinity, higher dose of PTH (7-34) might be effective. Secondly, the effects of PTH
(7-34) might be masked by the endogenous peptide. PTH (7-34) might be a useful
anabolic agent in the absence of PTH (1-34), but if administered in vivo, it will be acting
on a background of endogenous hormone. Our data suggest under those circumstances,
its beneficial effects may be lost or that long-term exposure, even in the presence of the
signal-modifying PTH (7-34), will still result in issues with bone resorption. Again, it is
possible that these deficiencies could be overcome by administering higher doses of PTH
Further studies in human osteoblast systems are required and longer-term studies in mice

85

devoid of endogenous PTH will be necessary to tease out the potential anabolic effects of
PTH (7-34) on bone formation.
In conclusion, we showed that both peptides in combination modified cAMP and
calcium responses compared to each peptide alone. PTH (7-34) is an inverse agonist for
cAMP and calcium, but in the presence of PTH (1-34), potency was lowered for cAMP,
while it was enhanced for calcium. ERK is activated by PTH (1-34) and PTH (7-34) in a
temporally distinct manner, but is totally abolished in the presence of both peptides. This
suggests that cAMP is the player for ERK-dependent increase in DNA synthesis seen
with PTH (1-34). Gene expression patterns in the presence of both peptides is similar to
PTH (1-34) alone. These data suggest that PTH (7-34) may not be beneficial in vivo as a
therapeutic option, since its effects are masked by the endogenous peptide.
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Appendix A
Growth Curves

Growth Curves: Effects of PTH peptides on Saos2 growth curves. Saos2 cells were
plated in 96 well clear bottom black walled plates. After 16-18 h, the medium was
removed and replaced with medium supplemented with 0.5% FBS. Cells were treated
with increasing concentrations of PTH (1-34), PTH (7-34) or increasing concentration of
PTH (1-34) with 1µM PTH (7-34). Growth curves were determined as described in
Methods. A) Day 2 B) Day 3 C) Day 4 D) Day4. The data are the means ± SEM for fold
change over basal for three independent experiments assayed in triplicate.
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Appendix B
Amplification and Melt curve Curve for real-time-qPCR

Fig.B1. Example of the amplification curve of the real time-qPCR experiment for
the 12 selected genes. Gene expression was calculated using the 2 (-ΔΔ CT) method and
expressed as a fold change difference in treated over untreated cells. The horizontal line
is the threshold above the basal level of fluorescence. CT over 35 is considered nonexpressed or negative. The controls, positive PCR controls (PPC), reverse transcriptase
(RT) and genomic DNA controls (GDC) were calculated and pass the specification
mentioned in the manufacturers hand book.

Fig.B2. Melt curve of Custom RT2 Profiler PCR Array. The presence of a single,
distinct peak in each real-time qPCR reaction confirms the presence of the desired
amplicon.
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Appendix C
Antibody Table
Antibody

Catalog Number

Purchased from

CDKN1A

2947

Cell Signaling Technologies

BCl-2

2872

Cell Signaling Technologies

C-fos

2250

Cell Signaling Technologies

RANKL

MAB6263-SP

PTH1R

MAB5709

R&D Systems

Runx2

05-1478

Millipore

β-actin

A5441

Sigma

p-ERK

4370S

Cell Signaling Technologies

p-Akt

9271S

Cell Signaling Technologies

Anti-Rabbit-HRP

7074S

Cell Signaling Technologies

Anti-Mouse-HRP

7076S

Cell Signaling Technologies

R&D Systems
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Appendix D
Validation by Western Blot
Protein levels of Runx2 in Saos2 cells treated with low (1 nM) and high (100 nM) dose
PTH (1-34), 1 µM PTH (7-34) and the combined treatment of high dose PTH (1-34) and
PTH (7-34) at 2 h had no change from basal as shown in Fig. -Appendix D–A. At 24 h,
although Runx2 mRNA was lower in PTH-treated cells (Fig.7A), protein levels did not
parallel changes in mRNA since PTH (1-34) increased Runx2 protein. Interestingly,
PTH (7-34) alone and in combination inhibited protein expression. The expression data
in Figure 7A are consistent with PTH suppressing the differentiation of Saos2 cells under
these conditions. Our assessment of RANKL show there was no change in mRNA (Fig.
7B) or protein levels at 2 h (Appendix D-B). However, at 24 h, high dose PTH (1-34)
increased protein level while both peptides decreased it (Appendix D- B), and these data
do not correspond with the mRNA data at 24 h and at this time we are not certain what
this means. p21Cip1 mRNA was decreased at 2 h in all treatments (Fig.8A) and protein
levels were comparable (Appendix D-C). At 24 h, protein levels correlate with mRNA
data either with no change or a decrease from basal. Changes observed in Bcl-2 protein
levels (Appendix D-D) at both time points were similar to mRNA data in Figure 7B. An
increase in c-fos protein was seen with PTH (1-34) and the combined treatment of PTH
(1-34) and PTH (7-34). These protein levels do not correlate with decreased mRNA
levels (Fig.9A) and could be explained by the inherently short-lived c-fos which is
stabilized by post-translation phosphorylation through ERK.(93) There was no change in
c-fos mRNA with any of the treatments at 24 h apart from PTH (7-34) which resulted in a
significant decrease. Similar changes were observed in c-fos protein levels with no
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detectable bands at 24 h with any of the treatments. There was no change in PTH1R
mRNA (Fig.9B) from time-matched basal but were significantly decreased by all
treatments at 24 h. Protein data matches mRNA at both time points with no detectable
band at 24h.

Appendix D: Validation of genes by western blotting: Saos2 cells were plated in 6
well dishes and grown to confluence. Cells were treated with 1 and 100 nM PTH (1-34),
1 µM PTH (7-34) or both peptides (100nM PTH (1-34) and 1µM PTH (7-34)) for 2 and
24 h. Protein was isolated, and SDS-PAGE and Western blotting was performed as
described in Methods. Genes from each group were selected for validation. A) Runx2 B)
RANKL C) p21cip1 D) Bcl-2 E) c-fos F) PTH1R. The blots were quantified using
BioRad Image Lab Software 5.2.1, normalized to β-actin, and the ratio is listed above the
blot.
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